

Subject Index—Volume 76

- No. 1, July 1, pp.1-162
 No. 2, July 15, pp. 163-342
 No. 3, August 1, pp. 343-540
 No. 4, August 15, pp. 541-714
 No. 5, September 1, pp. 715-918
 No. 6, September 15, pp.919-1112
 No. 7, October 1, pp.1113-1298

- No. 8, October 15, pp.1299-1490
 No. 9, November 1, pp.1491-1686
 No. 10, November 15, pp.1687-1882
 No. 10, November 15, Supplement, pp.1883-2180
 No. 11, December 1, pp.2181-2388
 No. 12, December 15, pp.2389-2602

A

- Abdominal ultrasound, in Hodgkin's disease staging, 1460
 Acquired immunodeficiency syndrome
 primary central nervous system in, radiation therapy for, 328
 primary CNS lymphoma in, 163 (editorial)
 Actinomycin D, for gestational trophoblastic disease, 2079
 Acute leukemia. *See* Leukemia
 Adenocarcinoma
 esophageal, early stage, prognosis of, 178
 lung, alpha-1-antichymotrypsin in, 1368
 Adenom
 colorectal, p21^{ras} mutations in, ELISA detection of, 201
 thyroid, in Chernobyl children, 900
 Adolescents, thyroid tumors in, after Chernobyl accident, 900
 Adriamycin. *See* Doxorubicin
 Adult acute lymphoblastic leukemia, at relapse, 985
 Advance directives, in cancer center ICU, 1268
 African Americans, breast cancer prognosis in, 268
 AIDS. *See* Acquired immunodeficiency syndrome
 Alcoholics, esophageal cancer screening in, 928
 Alpha₁-antitrypsin, in renal cell carcinoma, prognosis and, 1428
 Alpha-fetoprotein, concanavalin A affinity electrophoresis of, in hepatocellular carcinoma, 1139
 American Cancer Society, Fifth National Conference on Gynecologic Cancers, Nov. 15 Supplement
 Ampulla of Vater tumors, p53 in, 1150
 Anal cancer, combined modality therapy for, 1731
 Analgesia
 negligence in, 2181 (editorial)
 opioids in, 1283, 2181 (editorial), 2375
 Anemia
 cancer-associated, recombinant human erythropoietin for, 2319
 Diamond-Blackfan, hematologic malignancies and, 517
 Angiogenesis
 in lung adenocarcinoma, metastasis and, 915 (letter)
 molecular genetics and, 1874
 Angiography, magnetic resonance, in cranially irradiated acute lymphoblastic leukemia survivors, 1846
 Angiosarcoma, of head and neck, treatment of, 319
 Antiandrogen withdrawal syndrome, in prostate cancer, 1428
 Antibody, monoclonal. *See* Monoclonal antibodies
 Antibody-induced apoptosis, of gastric carcinoma cells, 550
 Anti-CEA monoclonal antibody BW 431/26, for colorectal cancer, 215
 alpha-1-Antichymotrypsin, in lung adenocarcinoma, 1368
 Antiemetic therapy
 granisetron with/without methylprednisolone vs. metoclopramide plus methylprednisolone in, 1821
 ondansetron vs. granisetron vs. tropisetron in, 343, 535 (letter)
 oral combination, for cisplatin/cyclophosphamide plus doxorubicin therapy, 774
 prochlorperazine-based vs. metoclopramide-based, in bone marrow transplantation, 2330
 Antigen(s)
 carcinoembryonic, in colonic cell line, 187
 Ki-67
 in malignant fibrous histiocytoma, 618
 in oligodendroglioma, prognosis and, 1809
 Lewis Y, in papillary serous peritoneal carcinoma, 429
 mucosal, in lung cancer, antibody specificity for, 1166
 proliferating cell nuclear. *See* Proliferating cell nuclear antigen
 prostate-specific
 after dexamethasone treatment, 96
 in Asian men, 463
 sialosyl Tn, in advanced gastric cancer, prognosis and, 1529
 squamous cell carcinoma
 in cervical cancer, 807
 in hypopharyngeal/laryngeal cancer, 758
 Thomsen-Friedenreich-related, in colorectal cancer, 1700
 tissue polypeptide, in cervical cancer, 807
 alpha₁-Antitrypsin, in renal cell carcinoma, prognosis and, 1428
 Apoptosis, antibody-induced, of gastric carcinoma cells, 550
 Appendix, epithelial noncarcinoid tumors and tumor-like lesions of, 2383 (letter)
 Aromatic amines, cancer and, 1445
 Asian men, prostate specific antigen levels in, 463
 Aspirin, esophageal carcinoma and, 1116

Astrocytoma

- in infants, survival in, 1685 (letter)
- molecular analysis at *NF1* locus in, 674
- Atrophic gastritis, gastric epithelial dysplasia and, 376
- Attenuated familial adenomatous polyposis, 2427
- Atypical Spitz-like childhood tumors, 1833
- Autoimmune thyroiditis, thyroid papillary carcinoma and, 2312
- Axillary nodal metastase
 - in breast cancer, 1491
 - in bronchogenic carcinoma, 803

B

- Basaloid-squamous carcinoma, nasopharyngeal, 1689
- Basic fibroblast growth factor, in men with/without prostate cancer, 2304
- Basic fibroblast growth factor receptor-directed sporin toxins, for ovarian teratocarcinoma, 79
- Bax, in uterine cancer, 2297
- B-cell chronic lymphocytic leukemia, cutaneous infiltrates of, at herpes scar sites, 26
- bcl-2, in uterine cancer, 2297
- Benzidine, cancer and, 1445
- Beta-glucuronidase, in urinary tract cancer screening, 473
- Bethesda System, for cervical cancer staging, 1914
- Biopsy
 - colposcopic, operator variability in, 1601
 - needle, mediastinal, 1065
- Bladder cancer
 - aromatic amines and, 1445
 - cisplatin, carboplatin, and methotrexate for, 1797
 - nuclear morphometry in, prognosis and, 1790
 - screening for, urinary beta-glucuronidase in, 473
 - superficial, radical cystectomy for, 833
- Blastoma, pulmonary, surgery and chemotherapy for, 1537
- Bone, Langerhan's cell histiocytosis of, 2471
- Bone densitometry, in multiple myeloma, 1559
- Bone marrow transplant
 - for advanced neuroblastoma, 1295 (letter)
 - with high-dose chemotherapy, hemolytic uremic syndrome after, 2338
 - oral mucositis in, laser therapy for, 2550
 - prochlorperazine-based vs. metoclopramide-based antiemetic therapy in, 2330
- Borderline ovarian tumors, 2138
- Brachial plexus, isolated metastases to, 1829
- Brachytherapy, for gynecologic cancer, 2143
- Brain tumors. *See also specific types*
 - in elderly, increasing incidence of, 1634
 - etiology of, 709
 - familial melanoma with, 1571
 - metastatic, recurrent, from lung cancer, management of, 765
- BRCA1 gene, in ovarian cancer, 1992
- Breakthrough fungemia, with hepatosplenic candidiasis, 2357
- Breast cancer
 - advanced, oral etoposide for, 2485
 - axillary lymph node involvement in, 1491
 - bilateral
 - chromosome abnormalities in, 250
 - p53 in, 2504
 - biological profile evaluation of, 2510
 - clinical trials for, ethical issues in, 1294 (letter)
 - CNS metastasis in, after paclitaxel, 232
 - conditional survival in, 237
 - conservative surgery for, surgical margin status after, prognosis and, 259
 - diet and, 2053
 - ductal in situ
 - continued late local recurrence in, 1197
 - treatment of, 1113 (editorial)
 - estrogen replacement therapy and, 2059, 2075
 - hormones and, 2059, 2075
 - inflammatory, treatment failure in, 2286
 - intraductal
 - 3-D imaging of, 32
 - pathologic findings in, 2385 (letter)
 - lymphatic and blood vessel invasion in, prognosis and, 1772
 - mastectomy for, reconstruction after, 2070
 - micrometastases in, reverse-transcriptase polymerase chain reaction for, 533 (letter)
 - oral contraceptives and, 2059
 - pregnancy and, prognosis and, 531 (letter)
 - prognosis in, ethnic factors in, 268
 - proliferative rate in, survival and, 1009
 - radiotherapy for
 - delay in, 2497
 - malignant pleural mesothelioma after, 437
 - relapse and contralateral tumor rates after, 2660
 - reproductive history in, prognosis and, 531 (letter)
 - risk of
 - familial ovarian cancer and, 1416
 - weight gain timing and, 243
 - screening for
 - benefits of, 1579
 - Canadian National Breast Cancer Screening Study for, 2107
 - controversies in, 2064
 - psychosocial issues in, 2133
 - training module for, 2125
 - in women under 50, 1579, 1679 (letter), 2064, 2097
 - small localized, recurrence predictors for, 2266
 - staging of, sociodemographic factors in, in southern Italy, 1585
 - survival in
 - hormone replacement therapy in, 2075
 - social support and, 631
 - treatment selection in, patient involvement in, 2275
 - tumor distribution in, 1 (editorial)
 - ultrasound detection of, 627
 - urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in, 998
- Breast cancer prevention trial, enrollment variables in, 46
- Breast cancer training module, longitudinal evaluation of, 2125
- Breast examination, training module for, 2125
- Breast reconstruction, postmastectomy, 2070

- Bromodeoxyuridine labeling index, in non-Hodgkin's lymphoma, prognosis and, 1059
- Bronchogenic carcinoma. *See also* Lung cancer
axillary nodal metastases in, 803
- Burkitt's lymphoma, Epstein-Barr viral sequences in, in Egypt, 1245
- C**
- CA 19-9, in colonic cell line, 187
- CA 125, in ovarian cancer screening, 2092
- Cachexia, as multifactorial syndrome, 2418
- E-Cadherin, in gastric cancer, 2193
- Camptothecins, for advanced ovarian cancer, 2028
- Canadian National Breast Cancer Screening Study, 2107
- Cancer. *See also specific sites and types*
advanced, multiple-cycle high-dose chemotherapy for, with hematopoietic progenitor cells, 860
childhood refractory, etoposide, ifosfamide and cisplatin for, 1686 (letter)
in hereditary hemochromatosis heterozygotes, 875
human chorionic gonadotropin- β as common biochemical denominator in, 1299 (editorial), 1467
relative survival rate in, 1687
second primary
after radiation-treated cervical cancer, 442
carcinoid tumors and, 106
in esophageal cancer, 101
in long-term rhabdomyosarcoma survivors, 1860
pancreatic cancer as, 589
in systemic sclerosis, 910
- Cancer at the Crossroads: A Report to Congress* (National Cancer Advisory Board), 135
- Cancer cachexia, as multifactorial syndrome, 2418
- Cancer care, economics of, 1886
- Cancer center ICU, advance directives in, 1268
- Cancer pain
management of, negligence in, 2181 (editorial)
opioids for, 1283, 2181 (editorial), 2375
- Cancer patients, communication with, 167
- Cancer registries, SEER, case reporting completeness in, 2343
- Candidiasis, hepatosplenic, chemotherapy continuation in, 2357
- Carboplatin
for nonsmall cell lung cancer, with radiation therapy, 530 (letter)
for urothelial cancer, 1797
- Carboxypeptidase-G₂ rescue, for methotrexate-induced nephrotoxicity, 521
- Carcinoembryonic antigen, in colonic cell line, 187
- Carcinoid tumors, excess cancer risk with, 106
- Carcinosarcoma, prostate, 1035
- Cartilaginous tumors, DNA content of, 1176
- Case reporting, in National Cancer Institute SEER Program, 2343
- Cathepsin, in gastric cancer, 367
- Cathepsins B and L, in laryngeal cancer, 1757
- CD44, in colonic cell line, 187
- Cell-mediated immunity, impaired, multiple skin cancers and, 228
- Cell surface markers, on colon cell line, 195
- Cemento-ossifying orbital fibroma, chromosome breakpoints in, 1853
- Central nervous system lymphoma
in AIDS, 163
radiation therapy for, 328
increasing incidence of, in elderly, 1634
- Central nervous system metastasis, in paclitaxel-treated breast cancer, 232
- Central nervous system tumors, familial melanoma with, 1571
- Central neurocytoma, positron emission tomography of, 1224
- Central pathology review, for clinical trials, 307
- c-erbB-2, in papillary thyroid cancer, prognosis and, 1643
- Cerebral metabolic rate of glucose, in central neurocytoma, 1224
- Cervical cancer. *See also* Gynecologic cancer
Bethesda System staging of, 1914
chemoprevention trials and surrogate end point biomarkers in, 1956
clear cell adenosquamous, 1591
early stage hysterectomy-treated, prognostic factors in, 1978
epidemiology of, 1888
HPV-negative, MDM2 amplification and p53 mutation in, 57
invasive, patterns of care for, 1934
molecular biology of, 1902
pathologic classification of, survival and, 1948
pretreatment markers in, 807
radiation therapy for, 2152
color Doppler assessment of, 67
second primary after, 442
screening for, future directions in, 1919
stage IIb bulky, intraarterial chemotherapy for, 814
Stage IIIB-IVA, intraarterial chemotherapy and radical surgery for, 1019
survival in, in high-risk urban population, 2518
- Cervical high-grade squamous epithelial lesions, treatment of, 1928
- Cervical neoplasia
advanced, T lymphocytes in, 1411
colposcopic detection and grading of, operator variability in, 1601
- Chemoembolization, for uveal melanoma metastatic to liver, 1665
- Chemoprevention, of hepatocellular carcinoma, Sho-siako-to (TJ-9) for, 743
- Chemotherapy. *See also specific agents*
for acute promyelocytic leukemia in pregnancy, 2242
for advanced ovarian cancer, 2028
for anal cancer, 1731
antiemetic therapy for
ondansetron vs. granisetron/tropisetron in, 343, 535 (letter)
oral combination, for cisplatin/cyclophosphamide plus doxorubicin therapy, 774
prochlorperazine-based vs. metoclopramide-based, in bone marrow transplant, 2330

- for breast cancer, clinical trials of enrollment variables in, 46
- ethical issues in, 1294 (letter)
- for cervical cancer, 1019, 1934
- for childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia, 339
- for colorectal cancer, 572, 961, 1709
 - for palliation, 1126
- for cranial centroblastic lymphoma, 1261
- for endometrial cancer, 2044
- for gastric cancer, 715, 1694
- for gestational trophoblastic disease, 2079
- for head and neck cancer, in recurrence, 1233
- in hepatosplenic candidiasis, 2357
- high-dose, with stem cell support, hemolytic uremic syndrome after, 2338
- for inflammatory breast cancer, failure of, 2286
- with interleukin-2 and interferon-alfa, rhabdomyolysis after, 678
- for lung cancer, vs. radiation therapy, 779
- for malignant mixed müllerian ovarian tumors, 1209
- for malignant pleural mesothelioma, 2230
- multiple-cycle high-dose, with hematopoietic progenitor cells, 860
- for nasal T-cell lymphoma, resistance to, 2351
- for nasopharyngeal cancer, 2186
- neoadjuvant intraarterial, for cervical cancer, 814
- for nonsmall cell lung cancer, with radiotherapy, 530 (letter), 593
- for papillary serous peritoneal carcinoma, 429
- for paraganglioma, 1476
- for pulmonary blastoma, 1537
- for small cell lung cancer, 406
- for soft tissue sarcoma, 2248
- for Stage IV head and neck cancer, with radiation therapy, 1653
- for urothelial cancer, 1797
- for uveal melanoma metastatic to liver, 1665
- for vulvar cancer, 2159
- Chernobyl accident, pediatric thyroid tumors after, 900
- Children. *See also specific childhood cancers, e.g.,* Leukemia
 - embryonal cancer in, after in vitro fertilization, 2372
 - granulocyte-macrophage colony-stimulating factor prophylaxis for, for neutropenia/infection prophylaxis, 510
 - melanoma and atypical Spitz-like tumors in, 1833
 - minimally invasive surgery in, 121
 - refractory solid tumors in, etoposide, ifosfamide and cisplatin for, 1686 (letter)
 - thyroid tumors in, after Chernobyl accident, 900
- Chinese, aggressive primary hepatic lymphoma in, 1336
- Cholangiocarcinoma, mass-forming intrahepatic, clinical classification of, 2449
- Cholecystectomy, survival and, 1145
- Chondrosarcoma
 - dedifferentiated, p53 in, 223
 - of jaw and facial bones, 1550
- Choriocarcinoma, diagnosis and treatment of, 2079
- Chromoendoscopy, for esophageal cancer screening, 919 (editorial)
- Chromosome 18 monosomy, in colorectal tumors, 1132
- Chromosome abnormalities, in bilateral breast cancer, 250
- Chromosome breakpoints, in cemento-ossifying orbital fibroma, 1853
- Chronic leukemia. *See* Leukemia
- Chronic lymphocytic thyroiditis, thyroid papillary carcinoma and, 2312
- Cigarette smoking, secondary pancreatic cancer and, 589
- Cirrhosis, hepatocellular carcinoma in, 915 (letter)
 - prevention in, Sho-siako-to (TJ-9) for, 743
- Cisplatin
 - for cervical cancer, 814
 - for gastric cancer, 1694
 - for head and neck cancer, in recurrence, 1233
 - with interleukin-2 and interferon-alfa, rhabdomyolysis after, 678
 - for malignant mixed müllerian ovarian tumors, 1209
 - for malignant pleural mesothelioma, 2230
 - for nasopharyngeal carcinoma, 2186
 - nausea and vomiting with
 - granisetron with/without methylprednisolone vs. metoclopramide plus methylprednisolone in, 1821
 - ondansetron vs. granisetron vs. tropisetron for, 343, 535 (letter)
 - oral combination antiemetics for, 774
 - for nonsmall cell lung cancer, with radiotherapy, 530 (letter), 593
 - for papillary serous peritoneal carcinoma, 429
 - for refractory childhood solid tumors, 1686 (letter)
 - for small cell lung cancer, 406
 - taxol neurotoxicity after, 916 (letter)
 - for urothelial cancer, 1797
 - for uveal melanoma metastatic to liver, 1665
- Cladribine, for hairy cell leukemia, hypercholesterolemia and, 423
- Clear cell adenosquamous carcinoma, of cervix, 1591
- Clear cell sarcoma, of kidney, after in vitro fertilization, 2372
- Clinical trials. *See also specific therapeutic modalities*
 - for breast cancer
 - enrollment variables in, 46
 - ethical issues in, 1294 (letter)
 - central pathology review for, 307
 - entry and evaluation of older patients in, 333
 - c-myc, in endometrial cancer, 2034
 - Colon cancer. *See* Colorectal cancer
 - Color Doppler ultrasound
 - in assessment of radiation therapy, for cervical cancer, 67
 - in ovarian cancer screening, 1214
 - Colorectal adenoma, p21^{ras} mutations in, ELISA detection of, 201
 - Colorectal adenoma-carcinoma sequence, FW6 epitope in, 954
 - Colorectal cancer. *See also* Rectal cancer
 - anti-CEA monoclonal antibody BW 431/26 for, 215

attenuated familial adenomatous polyposis and, 2427
curative resection for, survival after, 564
5-fluorouracil plus folinic acid for, 528, 559, 1126, 1330, 1709
FW6 epitope in, 955
genetics of, 2389 (editorial)
hepatic metastasis from, cryosurgery for, 210
in hereditary hemochromatosis heterozygotes, 875
hydroxyurea for, 1330
interferon alpha-2a for, 528 (letter)
monosomy 18 in, 1132
National Cancer Data Base report on, 538 (letter)
octreotide for, 572, 961
p2^{ras} mutations in, ELISA detection of, 201
³¹P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles in, 1715
postoperative surveillance in, tumor stage and, 1325
sialic acid residues in, 727
Thomsen-Friedenreich-related antigens in, 1700
Colorectal tumors, monosomy 18 in, 1132
Colposcopy, operator variability in, 1601
Communication, with cancer patients, 167
Computed tomograph
 in Hodgkin's disease staging, 1460
 spiral, of focal hepatic tumors, 2434
Computer imaging, 3-D, of intraductal extension of breast cancer, 32
Concanavalin A affinity electrophoresis of serum alpha-feto-protein, in hepatocellular carcinoma, 1139
Coping styles, patient communication and, 167
Cranial centroblastic lymphoma, chemotherapy for, 1261
Cranial irradiation, late effects of, magnetic resonance imaging/angiography of, 1846
C-reactive protein, in renal cell carcinoma, prognosis and, 1428
Critical care unit, decision making in, 2171
Cryotherapy, for hepatic metastase
 from colorectal cancer, 210
 from neuroendocrine tumors, 501
Cutaneous angiosarcoma, of head and neck, treatment of, 319
Cutaneous plexiform schwannoma, neurofibromatosis type 2 and, 1181
Cyclin 2389, esophageal squamous cell carcinoma and, 541
Cyclophosphamid
 with doxorubicin, oral combination antiemetics for, 774
 for gestational trophoblastic disease, 2079
 for malignant pleural mesothelioma, 2230
 multiple-cycle high-dose, with hematopoietic progenitor cells, 860
 for paraganglioma, 1476
 for small cell lung cancer, 406
Cyfra 21-1, in cervical cancer, 807
Cysts, epithelial, ovarian dysplasia and, 1027
Cystadenoma, mucinous, of lung, 1540
Cystectomy, radical, for superficial bladder cancer, 633
Cysteine proteases, in gastric cancer, 367
Cytokeratins, in vulvar squamous cell carcinoma, 638

D

Dacarbazin
 with interleukin-2 and interferon-alfa, rhabdomyolysis after, 678
 for paraganglioma, 1476
Dactinomycin, for gestational trophoblastic disease, 2079
Dermatitis, radiation recall, paclitaxel and, 1069
Der p1, in lung cancer, 1166
Desmoplasia and neurotropism, in melanoma, prognosis and, 2242
Dexverapamil, for pancreatic adenocarcinoma, 1356
Diamond-Blackfan anemia, hematologic malignancies and, 517
Dianisidine, cancer and, 1445
Diet. *See also* Nutrition
 breast cancer and, survival in, 275
 gallbladder cancer and, 1747
 serum hormones and menstrual function and, 2491
 vulvar cancer and, 2291
Disseminated intravascular coagulation, in acute promyelocytic leukemia, in pregnancy, 2242
DNA content
 in cartilaginous tumors, 1176
 in colorectal cancer, 1724
 prognosis and, 383
 in laryngeal cancer, 1757
 in neuroblastoma, 695
 in renal cell carcinoma, prognosis and, 296
Docetaxel
 for advanced ovarian cancer, 2028
 scleroderma-like lesions and, 110
Doppler ultrasound, in ovarian cancer screening, 1214
Doxorubicin
 with cyclophosphamide, oral combination antiemetics for, 774
 for malignant mixed müllerian ovarian tumors, 1209
 for malignant pleural mesothelioma, 2230
 for paraganglioma, 1476
 for small cell lung cancer, 406
Dyestuff workers, cancer in, 1445

E

E-cadherin, in gastric cancer, 941, 2193
Economic factors
 in cervical cancer survival, 2518
 in gynecologic cancer, 2176
Egypt, Burkitt's lymphoma in, Epstein-Barr viral sequences in, 1245
Elderly
 brain tumors in, increasing incidence of, 1633
 in clinical trials, 333
Embolization, transcatheter arterial, for hepatocellular carcinoma, portal circulation after, 736
Embryonal carcinoma, after in vitro fertilization, 2372
Endometrial cancer. *See also* Gynecologic cancer
 epidermal growth factor in, steroid hormone sensitivity and, 2524

- molecular basis of, 2034
 p53 mutation in, 72
 preoperative evaluation and staging of, 2041
 radiotherapy for, leukemia after, 644
 recurrent, management of, 2044
 risk factors for, 2044
 with synchronous endometrioid ovarian cancer, loss of heterozygosity in, 650
 tamoxifen for, 2044
- Endometrium, insulin-like growth factor and binding protein mRNA in, tamoxifen and, 1406
- Endoscopic esophageal mucosal resection, in esophageal cancer screening, 928
- Epidermal growth factor, in endometrial cancer, 2524
- Epidermal growth factor receptor, in papillary thyroid cancer, prognosis and, 1643
- Epirubicin
 for gastric cancer, 1694
 for nonsmall cell lung cancer, with radiation therapy, 530 (letter)
 for pancreatic adenocarcinoma, 1356
- Epirubicin-lipiodol, vs. ¹³¹I-lipiodol radiotherapy, for hepatocellular carcinoma, 2202
- Epithelial inclusion cysts, ovarian dysplasia and, 1027
- Epithelial noncarcinoid tumors and tumor-like lesions, of appendix, 2383 (letter)
- Epstein-Barr viral sequences, in Burkitt's lymphoma, in Egypt, 1245
- Epstein-Barr virus
 basaloid-squamous carcinoma of nasopharynx and, 1689
 penile carcinoma and, 658
- Epstein-Barr virus-related hepatic lymphoproliferative disorders, after liver transplant, 1344
- Epstein-Barr virus-related leiomyosarcoma, in liver transplant recipients, 1481
- Erratum, 1882
- Erythrocyte sedimentation rate, in renal cell carcinoma, prognosis and, 1428
- Erythropoietin, recombinant human, for cancer-associated anemia, 2319
- Esophageal cancer
 aspirin and, 1116
 associated head and neck cancer and, 101
 chromoendoscopic screening for, 919 (editorial)
 early-stage squamous cell vs. adenocarcinoma, prognosis of, 178
 human papillomavirus in, 1522
 metastases at presentation in, 1120
 screening for, by endoscopy and iodine staining, 928
 squamous cell
 cyclin 2389 and, 541
 histologic parameters in, prognosis and, 922
 MIB-1 proliferation index in, 358
- Estradiol, reduced serum, low-fat high-fiber diet and, 2491
- Estrogen, reduced serum, low-fat high-fiber diet and, 2491
- Estrogen receptor-related protein, in papillary thyroid cancer, prognosis and, 1643
- Estrogen replacement therapy
 in breast cancer etiology, 2059, 2075
 in breast cancer survivors, 2075
- Ethanol, percutaneous injection of, for hepatocellular carcinoma, 1737
- Ethical issues, in breast cancer clinical trials, 1294 (letter)
- Ethmoid sinus, chondrosarcoma of, 1550
- Ethnic factors
 in breast cancer prognosis, 268
 in prostate specific antigen levels, 463
- Etoposide
 for gestational trophoblastic disease, 2079
 multiple-cycle high-dose, with hematopoietic progenitor cells, 860
 for nonsmall cell lung cancer, with radiation therapy, 530 (letter)
 oral, for advanced breast cancer, 2485
 for refractory childhood solid tumors, 1686 (letter)
 for small cell lung cancer, 406
- Ewing's sarcoma, of pelvis, surgical indications for, 1388
- Extraskelatal osteosarcoma, course and survival in, 2253
- Extravasation, of paclitaxel, 116
- ## F
- Facial bones, chondrosarcoma of, 1550
- Fallopian tube cancer, *K-ras* mutation in, 86
- Familial adenomatous polyposis
 attenuated, 2427
 periampullary tumors in, growth factor expression and proliferation kinetics in, 187
- Familial cutaneous malignant melanoma, with nervous system tumors, 1571
- Familial medullary thyroid carcinoma, *RET* mutations in, 479
- Familial ovarian cancer
 molecular basis of, 1992, 1998
 overview of, 1998
- Fat, dietary
 breast cancer and, 275, 2053
 gallbladder cancer and, 1747
- Ferritin, in renal cell carcinoma, prognosis and, 1428
- alpha-Fetoprotein, concanavalin A affinity electrophoresis of, in hepatocellular carcinoma, 1139
- Fibroadenoma, progression of to phyllodes tumor, clonal analysis of, 1779
- Fibroblast growth factor, in men with/without prostate cancer, 2304
- Fibroma
 orbital, cemento-ossifying, chromosome breakpoints in, 1853
 psammomatoid ossifying, of sinonasal region, 1155
- Flexor fossae, soft tissue sarcoma of, prognostic factors in, 1398
- Flow cytometry. *See* DNA content
- 5-Fluorouracil
 for anal cancer, 1731
 for colorectal cancer, 1126
 with folinic acid and hydroxyurea, 1330
 with leucovorin, 559

- with leucovorin and interferon alpha-2a, 528 (letter)
- plus high-dose folinic acid with/without methyl-lomustine, 1709
- for gastric cancer, 1694
- with folinic acid, 715
- for head and neck cancer, in recurrence, 1233
- for nasopharyngeal cancer, 2186
- Flutamide withdrawal, in prostate cancer, 1428
- Folinic acid
 - with 5-fluorouracil
 - for colorectal cancer, 528 (letter), 559, 1126, 1330, 1709
 - for gastric cancer, 715
 - for nasopharyngeal cancer, 2186
- Follicular thyroid cancer, in Chernobyl children, 900
- Follow-up, tumor registry, 880
- Food. *See* Diet; Nutrition
- France, pain control and morphine prescribing in, 2375
- Fungemia, breakthrough, with hepatosplenic candidiasis, 2357
- FW6 epitope, in colorectal adenoma-carcinoma sequence, 955

G

- Galactosylgloboside, in seminoma, metastasis and, 1043
- Gallbladder cancer
 - resectional surgery for, survival and, 1145
 - risk factors for, 1747
- Gastric cancer
 - advanced, 5-fluorouracil and folinic acid for, 715
 - cysteine and serine proteases in, 367
 - E-cadherin in, 941
 - epirubicin, cisplatin, and 5-fluorouracil for, 1694
 - in hereditary hemochromatosis heterozygotes, 875
 - Japanese-type radical lymph node dissection for, 1302
 - p53 in, 720
 - SC-1 antibody-induced apoptosis in, 550
 - sialosyl Tn antigen in, prognosis and, 1529
 - submucosal, surgery for, 935
 - urokinase-type plasminogen activator in, 941
- Gastric epithelial dysplasia, management of, 376
- Gastric lymphoma, primary, prognostic factors in, 1313
- Gastritis, atrophic, gastric epithelial dysplasia and, 376
- Gastrointestinal cancer, radioimmunoassay for plasma glutathione S-transferase-pi in, 1363
- Gelatinase B:metalloproteinase complexes, 700
- Gemcitabine, for advanced ovarian cancer, 2028
- Genes. *See also specific genes and oncogenes*
 - tumor suppressor
 - in endometrial cancer, 2034
 - in ovarian cancer, 1992, 1998
- Gene therapy, 1878
- Genetics, molecular, U.S.-Italy workshop on, 1868, 1869, 1874, 1878
- Germ cell tumors
 - all-trans-retinoic acid for, 680
 - ovarian, p53 in, 291
- Gestational trophoblastic disease, diagnosis and treatment of, 2079
- Gliomas
 - etiology of, 709
 - increasing incidence of, in elderly, 1634
 - intracavitary interleukin-2 with lymphokine-activated killer cells for, 840
 - radiation therapy for, 307
- Glutathione S-transferase-pi, radioimmunoassay for, in gastrointestinal cancer, 1363
- Granisetron
 - vs. ondansetron, for nausea and vomiting, 343, 535 (letter)
 - vs. tropisetron, for nausea and vomiting, 343
 - with/without methylprednisolone, vs. metoclopramide plus methylprednisolone, for cisplatin nausea and vomiting, 1821
- Granulocyte-colony stimulating factor, for mucormycosis, in acute lymphoblastic leukemia, 895
- Granulocyte-macrophage colony-stimulating factor
 - lymphokine-activated killer cell function and, 1253
 - for neutropenia/infection prophylaxis, in children, 510
 - for pancreatic adenocarcinoma, 1356
- Growth factors
 - with multiple-cycle high-dose chemotherapy, 860
 - in perianapillary tumors, in familial adenomatous polyposis, 187
- Gynecologic cancer. *See also specific types*
 - brachytherapy for, 2143
 - matrix metalloproteinase vs. tissue inhibitor of metalloproteinase-1 in, 2565
 - operative laparoscopy for, 1987, 2113
 - screening for, psychosocial issues in, 2133
 - socioeconomic status and, 2176
 - survival in, psychosocial issues in, 2117

H

- Hairy cell leukemia, hypercholesterolemia in, 423
- Haptoglobin, in renal cell carcinoma, prognosis and, 1428
- Ha-ras, in neuroblastoma, 1086
- Ha-ras p21, in neuroblastoma, 695
- Hashimoto's thyroiditis, thyroid papillary carcinoma and, 2312
- Head and neck angiosarcoma, treatment of, 319
- Head and neck cancer
 - 11q13 rearrangements in, prognosis and, 853
 - with esophageal cancer, 101
 - second primary tumors and, 1684 (letter)
 - Stage IV, accelerated fractionated radiotherapy plus chemotherapy for, 1655
- Head and neck liposarcoma, 1051
- Hematologic malignancies, Diamond-Blackfan anemia and, 517
- Hematopoietic progenitor cells, with multiple-cycle high-dose chemotherapy, 860
- Hemolytic uremic syndrome, after high-dose chemotherapy with stem cell support, 2338
- Hepatic cirrhosis, hepatocellular carcinoma and, 915 (letter)
- Hepatic lymphoma
 - in Chinese, 1336
 - Epstein-Barr virus-related, after liver transplant, 1344

- Hepatic lymphoproliferative disorders, Epstein-Barr virus-related, after liver transplant, 1344
- Hepatic metastasis
from colorectal cancer
 cryosurgery for, 210
 Thomsen-Friedenreich-related antigens in, 1700
from neuroendocrine tumors, cryotherapy for, 501
from uveal melanoma, 1665
- Hepatic transplant, Epstein-Barr virus-related hepatic lymphoproliferative disorders after, 1344
- Hepatic tumors, spiral computed tomography of, 2434
- Hepatitis C virus genotypes, hepatocellular carcinoma and, 1352
- Hepatitis C virus RNA, in hepatocellular carcinoma, in situ hybridization detection of, 2211
- Hepatoblastoma, after in vitro fertilization, 2372
- Hepatocellular carcinoma
 cirrhosis and, 915 (letter)
 concanavalin A affinity electrophoresis of serum alpha-fetoprotein in, 1139
 epirubicin-lipiodol vs. ¹³¹I-lipiodol radiotherapy for, 2202
 hepatitis C virus genotypes and, 1352
 hepatitis C virus RNA in, in situ hybridization detection of, 2211
 pathologic features of, prognosis and, 2443
 percutaneous ethanol injection for, 1737
 portal circulation to, after transcatheter embolization, 736
 in pregnancy, 1678 (letter)
 prognostic factors in, in North America, 597
 proliferating cell nuclear antigen in, 399
 Sho-saiko-to (TJ-9) for prevention of, 743
- Hepatosplenic candidiasis, chemotherapy continuation in, 2357
- HER-2/*neu* oncogene, in ovarian cancer, 1992
- Hereditary hemochromatosis, heterozygosity for, disease risk in, 875
- Herpes scar sites, B-cell chronic lymphocytic leukemia infiltrates in, 26
- Histiocytoma, malignant fibrous
 Ki-67 antigen in, 618
 vs. osteosarcoma, in patients >40, 972
 p53 in, 618, 1187
- Histiocytosis, Langerhan's, of bone, 2471
- Hodgkin's disease, staging of, ultrasound and computed tomography in, 1460
- Hormone replacement therapy
 in breast cancer etiology, 2059, 2075
 in breast cancer survivors, 2075
- Hormones, breast cancer and, 2059, 2075
- Hormone therapy, for endometrial cancer, epidermal growth factor and, 2524
- ³H-thymidine-labeling index, in renal cell carcinoma, prognosis and, 299
- Human chorionic gonadotropin- β , as common biochemical denominator in cancer, 1299 (editorial), 1467
- Human immunodeficiency virus infection. *See also* Acquired immunodeficiency syndrome
- lymphoma in, chromosomal instability in, 1238
- nasopharyngeal lymphoid hyperplasia in, 527 (letter)
- Human papillomavirus
 in cervical cancer
 of clear cell adenosquamous type, 1591
 epidemiology of, 1888
 in esophageal cancer, 1522
 in oral squamous cell carcinoma, 1513
 screening for, 1919
- Hydroxyurea, with 5-fluorouracil, for colorectal cancer, 1330
- Hypercholesterolemia, in hairy cell leukemia, 423
- Hypopharyngeal cancer, squamous cell carcinoma antigen in, 758
- Hypothyroidism, after ¹³¹I-metaiodobenzylguanidine, for neuroblastoma, 1662
- Hysterectomy, for cervical cancer, 1934
 prognostic factors and, 1978
- ## I
- Ifosfamide
 nephrotoxicity of, 2557
 for refractory childhood solid tumors, 1686 (letter)
 renal failure after, 497
- ¹³¹I-metaiodobenzylguanidine, for neuroblastoma, 1662
- Immunity, impaired cell-mediated, multiple skin cancers and, 228
- Immunotherapy. *See also specific agents*
 for colorectal cancer, with 5-fluorouracil and leucovorin, 528 (letter)
 for head and neck cancer, in recurrence, 1233
 with interferon- α and chemotherapy, rhabdomyolysis after, 678
 lymphokine-activated killer cell function and, 1253
 for metastatic renal cell carcinoma, 1629
 myositis and, 1219
 polyethylene glycol-modified, for melanoma and renal cell carcinoma, 687
 for renal cell carcinoma, 687, 824
 rhabdomyolysis after, 678
 with/without lymphokine-activated killer cells, for renal cell carcinoma, 824
- Infants. *See also Children*
 embryonal cancer in, after in vitro fertilization, 2372
- Infections, granulocyte-macrophage colony-stimulating factor prophylaxis for, in children, 510
- Infertility, in vitro fertilization for, embryonal cancer after, 2372
- Inflammatory myoblastic tumor, of larynx, 2217
- Inflammatory pseudotumor, of lung, clonal changes in, 1545
- Infusion site injury, from paclitaxel, 116
- Insulin-like growth factor and binding protein mRNA, in endometrium, tamoxifen and, 1406
- Intensive care unit
 cancer center, advance directives in, 1268
 decision making in, 2171
- Interferon- α
 for head and neck cancer, in recurrence, 1233

- with interleukin-2 and chemotherapy, rhabdomyolysis after, 678
- Interferon alpha-2a, for colorectal cancer, with 5-fluorouracil and leucovorin, 528 (letter)
- Interleukin-2
- granulocyte-macrophage colony-stimulating factor with, 1253
 - with interferon-alpha and chemotherapy, rhabdomyolysis after, 678
 - with lymphokine-activated killer cells, for glioma, 840
 - myositis and, 1219
 - polyethylene glycol-modified, for melanoma and renal cell carcinoma, 687
 - with/without lymphokine-activated killer cells, for renal cell carcinoma, 824
- Interleukin-4, for metastatic renal cell carcinoma, 1629
- Interleukin-2 receptor alpha, in benign/malignant ovarian cancer, 1615
- In vitro fertilization, embryonal cancer after, 2372
- Involucrin, in vulvar squamous cell carcinoma, 638
- Iodine staining, in esophageal cancer screening, 928
- Iron stores, disease risk and, 875
- J**
- Japan, prostate cancer screening in, 463
- Japanese-type radical lymph node dissection, for gastric cancer, 1302
- Jaw, chondrosarcoma of, 1550
- K**
- Keratocanthoma, microsatellite instability in, 1765
- Ki-67 antigen
- in malignant fibrous histiocytoma, 618
 - in oligodendroglioma, prognosis and, 1809
- Ki-67 cell index
- in colorectal carcinoma, after octreotide, 572
 - in renal cell carcinoma, prognosis and, 296
- Kidney. *See also under* Renal
- clear cell sarcoma of, after in vitro fertilization, 2372
- K-ras
- in endometrial cancer, 2034
 - in fallopian tube cancer, 86
 - in ovarian cancer, 1992
- L**
- Labeling index, in non-Hodgkin's lymphoma, prognosis and, 1059
- Langerhan's cell histiocytosis of bone, 2471
- Laparoscopy, operative, for gynecologic cancer, 1987, 2113
- Laryngeal cancer
- DNA content and cathepsins B and L in, 1757
 - squamous cell carcinoma antigen in, 758
- Laryngeal inflammatory myoblastic tumor, 2217
- Laser therapy
- for oral mucositis, in bone marrow transplant recipients, 2550
 - for vulvar cancer, 2159
- Leiomyosarcoma
- Epstein-Barr virus-associated, after liver transplant, 1481
 - of prostate, 1422
- Lethal midline granuloma, p-glycoprotein/MDR1 in, 2351
- Leucovorin
- with 5-fluorouracil
 - for colorectal cancer, 528 (letter), 559, 1126, 1330, 1709
 - for gastric cancer, 715
 - for nasopharyngeal carcinoma, 2186
- Leukemia
- acute lymphoblastic
 - biology and treatment of, 2393
 - late effects of cranial irradiation in, magnetic resonance imaging/angiography of, 1846
 - mitoxantrone for, in children, 339
 - mucormycosis in, 895
 - myeloid markers in, 1564
 - at relapse, in adults, 985
 - T-cell, mitoxantrone for, 339
- acute promyelocytic
 - all-trans* retinoic acid for, cost-benefits of, 603
 - pregnancy in, 2242
- after radiation therapy for endometrial cancer, 644
 - chronic lymphocytic
 - cutaneous infiltrates of, at herpes scar sites, 26
 - transformation of to true-histiocytic lymphoma, 609
 - chronic myelogenous, Ph-positive, breakpoint site in, 992
 - Diamond-Blackfan anemia and, 517
 - hairy cell, hypercholesterolemia in, 423
 - in hereditary hemochromatosis heterozygotes, 875
- Lewis Y antigen, in papillary serous peritoneal carcinoma, 429
- Lipiodol-epirubicin, vs. ¹³¹I-lipiodol radiotherapy, for hepatocellular carcinoma, 2202
- Liposarcoma
- head and neck, 1051
 - p53 in, 1187
- Liver. *See also under* Hepatic; Hepatocellular
- metastasis to
 - from colorectal cancer
 - cryosurgery for, 210
 - Thomsen-Friedenreich-related antigens in, 1700 - from neuroendocrine tumors, cryotherapy for, 501
 - from uveal melanoma, 1665
 - spiral computed tomography of, 2434
- Liver transplant, Epstein-Barr virus-related hepatic lymphoproliferative disorders after, 1344
- Living will, in cancer center ICU, 1268
- Lomustine, for small cell lung cancer, 406
- Lower extremity, scleroderma-like lesions of, docetaxel and, 110
- Lung(s). *See also under* Pulmonary
- blastoma of, surgery and chemotherapy for, 1537
 - inflammatory pseudotumor of, clonal changes in, 1545

- metastasis to, in rectal cancer, surgery for, 393
 - mucinous cystadenoma of, 1540
 - mucormycosis of, in acute lymphoblastic leukemia, 895
 - Lung cancer**
 - adenocarcinoma, angiogenesis in, metastasis and, 915 (letter)
 - alpha-1-antichymotrypsin in, 1368
 - axillary nodal metastases in, 803
 - mucosal antigens in, antibody specificity for, 1166
 - nonsmall cell
 - blood and lymphatic vessel invasion in, 2464
 - with intrapulmonary metastases, 2464
 - p53 and *ras* p21 in, 2457
 - prognostic factors in, 2457, 2464
 - radiation therapy for, with/without chemotherapy, 593, 779
 - radiochemotherapy for, 530 (letter), 593, 779
 - recurrent brain metastases in, management of, 765
 - stage I, treatment and recurrence in, 787
 - transferrin receptor in, 20
 - primary lymphoepithelioma-like, 413
 - secondary pancreatic cancer in, 589
 - small cell, chemotherapy and radiotherapy for, 406
 - squamous cell, mean nuclear volume in, prognosis and, 797
 - in systemic sclerosis, 910
 - Lymph node dissection, Japanese-type, for gastric cancer,** 1302
 - Lymph node metastasis**
 - axillary
 - in breast cancer, 1491
 - reverse-transcriptase polymerase chain reaction for, 533 (letter)
 - in bronchogenic carcinoma, 803
 - in prostate cancer, frozen section examination of, 661
 - Lymphocytes, T, in advanced cervical neoplasia,** 1411
 - Lymphocytic thyroiditis, thyroid papillary carcinoma and,** 2312
 - Lymphoepithelioma-like lung cancer,** 413
 - Lymphokine-activated killer cells**
 - granulocyte-macrophage colony-stimulating factor and, 1253
 - with interleukin-2, for renal cell carcinoma, 824
 - Lymphoma**
 - Burkitt's, Epstein-Barr viral sequences in, in Egypt, 1245
 - central nervous system
 - in AIDS, 163 (editorial)
 - radiation therapy for, 328
 - in elderly, increasing incidence of, 1634
 - centroblastic cranial, chemotherapy for, 1261
 - Diamond-Blackfan anemia and, 517
 - gastric, prognostic factors in, 1313
 - hepatic
 - in Chinese, 1336
 - Epstein-Barr virus-related, after liver transplant, 1344
 - in hereditary hemochromatosis heterozygotes, 875
 - in HIV infection, chromosomal instability in, 1238
 - Hodgkin's, staging of, ultrasound and computed tomography in, 1460
 - labeling index in, prognosis and, 1059
 - S-phase fraction in, prognosis and, 1059
 - T-cell
 - mitoxantrone for, in children, 339
 - nasal
 - p-glycoprotein/MDR1 in, 2351
 - as proliferation of large granular leukocytes with CD3 phenotype, 537 (letter)
 - true histiocytic, transformation of chronic lymphocytic leukemia to, 609
 - Lymphoproliferative disorders, hepatic**
 - in Chinese, 1336
 - Epstein-Barr virus-related, after liver transplant, 1344
 - Lysosomal cathepsins B and L, in laryngeal cancer,** 1757
- M**
- Magnetic resonance angiography/imaging, in cranially irradiated acute lymphoblastic leukemia survivors,** 1846
 - Malignant fibrous histiocytoma**
 - Ki-67 antigen in, 618
 - vs. osteosarcoma, in patients >40, 972
 - p53 in, 618, 1187
 - Malignant glioma**
 - etiology of, 709
 - increasing incidence of, in elderly, 1634
 - intracavitary interleukin-2 with lymphokine-activated killer cells for, 840
 - radiation therapy for, 307
 - Malignant lymphoma. See Lymphoma**
 - Malignant melanoma. See Melanoma**
 - Malignant meningitis, presenting with neuropsychiatric manifestations,** 1804
 - Malignant mesothelioma, pleural**
 - after radiation-treated breast cancer, 437
 - cyclophosphamide, doxorubicin and cisplatin for, 2230
 - Malignant mixed müllerian ovarian tumors, cytoreduction and chemotherapy for,** 1209
 - Malignant pericardial effusion,** 1377
 - Malignant spindle cell tumor of larynx, inflammatory myoblastic tumor simulating,** 2217
 - Mammography**
 - benefits of, 1579
 - Canadian National Breast Cancer Screening Study for, 2107
 - controversies in, 2064
 - training module for, 2125
 - in women under 50, 1579, 1679 (letter), 2064, 2097
 - Mandible, chondrosarcoma of,** 1550
 - Mass-forming intrahepatic cholangiocarcinoma, clinical classification of,** 2449
 - Mastectomy, reconstruction after,** 2070
 - Matrix metalloproteinase, vs. tissue inhibitor of metalloproteinase-1, in gynecologic cancer,** 2565
 - Maxillary chondrosarcoma,** 1550
 - Maxillary sinus, chondrosarcoma of,** 1550
 - MDM2**
 - in HPV-negative cervical cancer, 57
 - in thyroid cancer, 341

- MDR1*, in nasal T-cell lymphoma, 2351
Mediastinal needle biopsy, 1065
Medullary thyroid cancer, *RET* mutations in, 479
Melanoma
 biochemotherapy for, rhabdomyolysis after, 678
 childhood, 1833
 desmoplasia and neurotropism in, prognosis and, 2242
 familial, with nervous system tumors, 1571
 polyethylene glycol-modified interleukin-2 for, 687
 surgery for, 2384 (letter)
 uveal, metastatic to liver, treatment of, 1665
Meningitis, malignant, presenting with neuropsychiatric manifestations, 1804
Menstrual function, low-fat high-fiber diet and, 2491
Mesothelioma, pleural
 after radiation-treated breast cancer, 437
 cyclophosphamide, doxorubicin and cisplatin for, 2230
131-I-Metaiodobenzylguanidine, for neuroblastoma, hypothyroidism after, 1662
Metalloproteinase complexes, tissue inhibitors of, 700
Metastasis
 brain, from lung cancer, management of, 765
 central nervous system, in paclitaxel-treated breast cancer, 232
 in esophageal cancer, at presentation, 1120
 hepatic
 from colorectal cancer
 cryosurgery for, 210
 Thomsen-Friedenreich-related antigens in, 1700
 from neuroendocrine tumors, cryotherapy for, 501
 from uveal melanoma, 1665
 isolated, to brachial plexus, 1829
 in lung cancer, angiogenesis and, 915 (letter)
 nodal
 axillary
 in breast cancer, 1491
 reverse-transcriptase polymerase chain reaction for, 533 (letter)
 in bronchogenic carcinoma, 803
 in prostate cancer, frozen section examination of, 661
 ovarian, from prolactin-secreting pituitary carcinoma, 1814
 in prostate cancer, postoperative, without prostate-specific antigen elevation, 2530
 pulmonary, in rectal cancer, surgery for, 393
 spinal, from solid tumors, survival and, 1453
Methionine-deprived total parenteral nutrition, protein turnover and, 1275
Methotrexate
 for gestational trophoblastic disease, 2079
 nephrotoxicity of, carboxypeptidase-G₂ rescue for, 521
 for urothelial cancer, 1797
Methyl-lomustine, with 5-fluorouracil and leucovorin, for colorectal cancer, 1709
Metoclopramide
 plus methylprednisolone, vs. granisetron with/without methylprednisolone, for cisplatin nausea and vomiting, 1821
 vs. prochlorperazine, in bone marrow transplant, 2330
MIB-1 proliferation index, in esophageal squamous cell carcinoma, 358
Mitomycin-C
 for anal cancer, 1731
 for cervical cancer, 814
Mitoxantrone
 for childhood T-cell lymphoma/T-cell acute lymphoblastic leukemia, 339
 multiple-cycle high-dose, with hematopoietic progenitor cells, 860
Mixed müllerian ovarian tumors, cytoreduction and chemotherapy for, 1209
Molar pregnancy, diagnosis and treatment of, 2079
Molecular genetics of cancer, U.S.-Italy workshop on, 1868, 1869, 1874, 1878
Monoclonal antibodies, in ovarian cancer detection and treatment, 2016
Monoclonal antibody BW 431/26, for colorectal cancer, 215
Monoclonal antibody FW6 epitope, in colorectal adenoma-carcinoma sequence, 955
alpha-3/4-Monofucosylated polylactosaminoglycan epitope, in colorectal adenoma-carcinoma sequence, 955
Monosomy 18, in colorectal tumors, 1132
Morphine, for cancer pain, 1283, 2181 (editorial), 2375
Mucinous cystadenoma, of lung, 1540
Mucormycosis, in acute lymphoblastic leukemia, 895
Mucosal antigens, in lung cancer, antibody specificity for, 1166
Mucositis, laser therapy for, in bone marrow transplant recipients, 2550
Multiple endocrine neoplasia type 2, *RET* mutations in, 479
Multiple myeloma, bone densitometry in, 1559
Mutations. *See specific mutations*
Myelodysplastic syndromes, clinical spectrum of, 869
Myeloid markers, in acute lymphocytic leukemia, 1564
Myeloma, bone densitometry in, 1559
Myositis, interleukin-2 and, 1219
- N**
Naphthylamine, cancer and, 1445
Narcotics, for cancer pain, 1283, 2181 (editorial), 2375
Nasal septum, chondrosarcoma of, 1550
Nasal T-cell lymphoma
 p-glycoprotein/*MDR1* in, 2351
 as proliferation of large granular leukocytes with CD3 phenotype, 537 (letter)
Nasopharyngeal cancer
 basaloid-squamous, 1689
 cisplatin, leucovorin and 5-fluorouracil for, 2186
Nasopharyngeal lymphoid hyperplasia, in HIV-1 infection, 527 (letter)
National Breast Cancer Screening Study (Canada), 2107
National Cancer Data Base report
 on colorectal cancer, 538 (letter)
 on ovarian cancer, 1096
 on pancreatic cancer, 1671
 on prostate cancer, 1096

- National Cancer Institute SEER Program, hospital case reporting completeness in, 2343
- National Surgical Adjuvant Breast Project, pathologic findings in intraductal carcinoma in, 2385 (letter)
- Nausea and vomiting
 with cisplatin/cyclophosphamide plus doxorubicin, oral combination antiemetics for, 774
 cisplatin-induced, granisetron with/without methylprednisolone vs. metoclopramide plus methylprednisolone for, 1821
 ondansetron vs. granisetron/tropisetron for, 343, 535 (letter)
- prochlorperazine- vs. metoclopramide-based therapy for, in bone marrow transplantation, 2330
- Needle biopsy, mediastinal, 1065
- Negligence, in pain management, 2181 (editorial)
- Nephrotoxicity
 of ifosfamide, 2557, 497
 methotrexate-induced, carboxypeptidase-G₂ rescue in, 521
- Nerve system injury, taxol-induced, after cisplatin treatment, 916 (letter)
- Nervous system. *See also under* Central nervous system
- Nervous system tumors, familial melanoma with, 1571
- Neural networks, in ovarian dysplasia classification, 1027
- Neuroblastoma
 advanced, bone marrow transplant for, 1295 (letter)
 in children >1 yr, 890
 DNA ploidy and Ha-ras p21 in, 695
 ¹³¹I-metaiodobenzylguanidine for, hypothyroidism after, 1662
 olfactory, 4
 screening for, 2363
 trk A in, 1086
- Neurocytoma, central, positron emission tomography in, 1224
- Neurofibromatosis
 astrocytoma in, molecular analysis at NF locus in, 674
 type 2, cutaneous plexiform schwannoma and, 1181
- Neuropsychiatric manifestations, malignant meningitis presenting as, 1804
- Neurotoxicity, of taxol, after cisplatin treatment, 916 (letter)
- Neurotropism and desmoplasia, in melanoma, prognosis and, 2242
- Neutropenia
 granulocyte-macrophage colony-stimulating factor prophylaxis for, in children, 510
 hepatosplenic candidiasis and, 2357
- N-myc, in neuroblastoma, 695, 1086
- Nodal dissection, Japanese-type, for gastric cancer, 1302
- Nodal metastasis
 axillary
 in breast cancer, 1491
 reverse-transcriptase polymerase chain reaction for, 533 (letter)
 in bronchogenic carcinoma, 803
 in prostate cancer, frozen section examination of, 661
- Non-Hodgkin's lymphoma. *See* Lymphoma
- Nuclear accident at Chernobyl, pediatric thyroid tumors after, 900
- Nuclear morphometry, prognosis and
 in bladder cancer, 1790
 in renal cell carcinoma, 1440
- Nutrition
 breast cancer and, 2053
 survival in, 275
 gallbladder cancer and, 1747
 serum hormones and menstrual function and, 2491
 total parenteral, methionine-deprived, protein turnover and, 1275
 vulvar cancer and, 2291
- O**
- Obesity
 breast cancer risk/prognosis and, 243, 268, 275
 gallbladder cancer and, 1747
- Octreotide, for colorectal cancer, 572, 961
- Olfactory neuroblastoma, 4
- Oligodendroglioma, proliferating cell nuclear antigen and Ki-67 in, 1809
- Oncogenes. *See also specific oncogenes*
 in endometrial cancer, 2034
 in ovarian cancer, 1992, 1998
- Oncology registries, follow-up methods of, 880
- Oncoproteins, in papillary thyroid cancer, prognosis and, 1643
- Ondansetron
 vs. granisetron, for nausea and vomiting, 343, 535 (letter)
 vs. tropisetron, for nausea and vomiting, 343
- Operative laparoscopy, for gynecologic cancer, 1987
- Opioids, for cancer pain, 1283, 2181 (editorial), 2375
- Oral contraceptive
 breast cancer and, 2059
 epithelial ovarian cancer and, 284
- Oral mucositis, laser therapy for, in bone marrow transplant recipients, 2550
- Oral squamous cell carcinoma
 human papillomavirus in, 1513
 p53 in, 1513
 proliferating cell nuclear antigen in, 1513
- Orbital fibroma, cemento-ossifying, chromosome breakpoints in, 1853
- Orosomucoid, in renal cell carcinoma, prognosis and, 1428
- Osteosarcoma
 extraskelatal, course and survival in, 2253
 vs. malignant fibrous histiocytoma, in patients >40, 972
- Ovarian cancer. *See also* Gynecologic cancer
 advanced, treatment advances in, 2028
 endometrioid, with synchronous endometrial cancer, loss of heterozygosity in, 650
 epithelial
 p53 in, 1201
 reproductive factors and, 284
 familial
 molecular basis of, 1992
 nonovarian cancer risk in, 1416
 overview of, 1998
 molecular basis of, 1992, 1998

- monoclonal antibodies for, in detection and treatment, 2016
- National Cancer Data Base report on, 1096
- p53 in, 291
- recurrent, secondary cytoreductive surgery for, 1606
- saporin toxins for, 79
- screening for
- algorithm for, 2004
 - psychosocial issues in, 2133
 - tumor markers in, 2092
 - ultrasonography in, 1214, 2086
 - ultrasound in, 2011
- soluble interleukin-2 receptor alpha in, 1615
- Ovarian dysplasia, in epithelial inclusion cysts, 1027
- Ovarian metastases, from prolactin-secreting pituitary carcinoma, 1814
- Ovarian tumors
- benign, soluble interleukin-2 receptor alpha in, 1615
 - borderline, 2138
 - germ cell, *all-trans*-retinoic acid for, 680
 - malignant mixed müllerian, cytoreduction and chemotherapy for, 1209
- OVX1, in ovarian cancer screening, 2092
- P**
- p2^{ras}
- in colorectal adenoma/carcinoma, ELISA detection of, 201
 - in nonsmall cell lung cancer, 2457
 - in papillary thyroid cancer, prognosis and, 1643
- p29 protein, in papillary thyroid cancer, prognosis and, 1643
- p53
- in ampulla of Vater tumors, 1150
 - in bilateral breast cancer, 2504
 - in dedifferentiated chondrosarcoma, 223
 - in endometrial cancer, 72, 2034
 - in epithelial ovarian carcinoma, 1201
 - in gastric cancer, 720
 - in HPV-negative cervical cancer, 57
 - in liposarcoma, 1187
 - in malignant fibrous histiocytoma, 618, 1187
 - in nonsmall cell lung cancer, 2457
 - in oral squamous cell carcinoma, 1513
 - in ovarian cancer, 1992
 - in ovarian germ cell tumors, 291
 - in vulvar cancer, 1786
- Paclitaxel
- for advanced ovarian cancer, 2028
 - for advanced soft tissue sarcoma, 2248
 - for breast cancer, CNS metastasis after, 232
 - infusion site injuries from, 116
 - peripheral neurotoxicity of, after cisplatin treatment, 916 (letter)
 - pneumonitis and, 1069
 - radiation recall dermatitis and, 1069
- Pain management
- negligence in, 2181 (editorial)
 - opioids in, 1283, 2181, 2375
- Pancreatic cancer
- dexverapamil, epirubicin, and granulocyte-macrophage-colony stimulating factor for, 1356
 - early diagnosis of, pure pancreatic juice cytology in, 750
 - hepatic metastases from, cryotherapy for, 501
 - National Cancer Data Base report on, 1671
 - as second primary, 589
- Papillary renal tumors, 669
- Papillary serous peritoneal carcinoma, in women, 429
- Papillary thyroid cancer, oncoproteins in, prognosis and, 1643
- Paraganglioma, chemotherapy for, 1476
- Paranasal sinuses, chondrosarcoma of, 1550
- Parenteral nutrition, methionine-deprived, protein turnover and, 1275
- Parity, epithelial ovarian cancer and, 284
- Pelvic lymph nodes, frozen section examination of, in prostate cancer, 661
- Pelvis, Ewing's sarcoma of, surgical indications for, 1388
- Penile carcinoma, Epstein-Barr virus infection and, 658
- Percutaneous ethanol injection, for hepatocellular carcinoma, 1737
- Pericardial effusion, malignant, 1377
- Peripheral nerves. *See also* Nervous system
- isolated metastases to, 1829
- Peripheral neurotoxicity, of taxol, after cisplatin treatment, 916 (letter)
- Peritoneal cancer, papillary serous, in women, 429
- P-glycoprotein/MDR1, in nasal T-cell lymphoma, 2351
- Phosphatic metabolite nuclear magnetic resonance profiles, in colon cancer, 1715
- Phospholipid nuclear magnetic resonance profiles, in colon cancer, 1715
- Phyllodes tumor, fibroadenoma progression to, clonal analysis in, 1779
- Pituitary cancer, prolactin-secreting, with cheek pouch implants and ovarian metastases, 1814
- Pituitary tumors, tumor viruses and, 490
- Placental site trophoblastic tumor, diagnosis and treatment of, 2079
- Plasma cell granuloma, of lung, clonal changes in, 1545
- Plasma glutathione S-transferase-pi, radioimmunoassay for, in gastrointestinal cancer, 1363
- Plasminogen activator inhibitor-1
- in breast cancer, 998
 - in gastric cancer, 367
- Pleural malignant mesothelioma
- after radiation-treated breast cancer, 437
 - cyclophosphamide, doxorubicin and cisplatin for, 2230
- Ploidy. *See* DNA content
- Pneumonitis, paclitaxel and, 1069
- ³¹P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles, in colon cancer, 1715
- Polyethylene glycol-modified interleukin-2, for melanoma and renal cell carcinoma, 687
- Polymerase chain reaction, in breast cancer, for micrometastases detection, 533 (letter)
- Polymorphic reticulosis, as proliferation of large granular leukocytes with CD3 phenotype, 537 (letter)
- Polyomaviral DNA, in pituitary tissue, 490

- Positron emission tomography, of central neurocytoma, 1224
- Poverty
cervical cancer survival and, 2518
gynecologic cancer and, 2176
- Pregnancy
in acute promyelocytic leukemia, 2242
hepatocellular carcinoma in, 1678 (letter)
later breast cancer prognosis and, 531 (letter)
molar, diagnosis and treatment of, 2079
- Primary CNS lymphoma, in AIDS, 163 (editorial)
radiation therapy for, 328
- Prochlorperazine-based antiemetic therapy, vs. metoclopramide-based therapy, in bone marrow transplantation, 2330
- Progesterone, sensitivity to, in endometrial cancer, epidermal growth factor and, 2524
- Prolactin-secreting pituitary carcinoma, with cheek pouch implants and ovarian metastases, 1814
- Proliferating cell nuclear antigen
in hepatocellular carcinoma, 399
in oligodendroglioma, prognosis and, 1809
in oral squamous cell carcinoma, 1513
in renal cell carcinoma, prognosis and, 296
- Prostate cancer
antiandrogen withdrawal in, 1428
dexamethasone for, 96
early detection of, in Japan, 463
frozen section examination of pelvic lymph nodes in, 661
high-grade, postoperative survival in, 2535
National Cancer Data Base report on, 1096
postoperative distant metastases in, without prostate-specific antigen elevation, 2530
radiation therapy for, detection of residual disease after, 1682 (letter)
risk of, familial ovarian cancer and, 1416
screening for, European randomized study of, 129
serum basic fibroblast growth factor in, 2304
Stage C, surgery plus radiotherapy for, 1621
Stage 2393, mean nuclear volume of, prognosis and, 91
suramin for, 453
surgery for, 1682 (letter)
- Prostate carcinosarcoma, 1035
- Prostatectomy, radical
distant metastases after, without prostate-specific antigen elevation, 2530
for high-grade cancer, survival after, 2535
indications for, 1682 (letter)
- Prostate leiomyosarcoma, 1422
- Prostate-specific antigen
after dexamethasone treatment, 96
in Asian men, 463
- Psammomatoid ossifying fibromas, of sinonasal region, 1155
- Psychiatric disturbances, malignant meningitis presenting with, 1804
- Psychosocial issues
in gynecologic cancer screening, 2138
in gynecologic cancer survivorship, 2117
- Pulmonary. *See also under Lung(s)*
Pulmonary blastoma, surgery and chemotherapy for, 1537
Pulmonary inflammatory pseudotumor, clonal changes in, 1545
Pulmonary metastases, in rectal cancer, surgical treatment of, 393
Pulmonary mucormycosis, in acute lymphoblastic leukemia, 895
Pure pancreatic juice, cytologic examination of, in detection of early pancreatic cancer, 750
- ## Q
- Questionnaires, tumor registry, in follow-up, 880
- ## R
- Race, gallbladder cancer and, 1747
- Racial factor
in breast cancer prognosis, 268
in prostate specific antigen levels, 468
- Radiation exposure, pediatric thyroid tumors after, 900
- Radiation recall dermatitis, paclitaxel and, 1069
- Radiation therapy
adjuvant, for Stage C prostate cancer, 1621
for anal cancer, 1731
brachytherapy, for gynecologic cancer, 2143
for breast cancer
delay in, 2497
malignant pleural mesothelioma after, 437
relapse and contralateral tumor rates after, 2660
for cervical cancer, 2152
color Doppler assessment of, 67
second primary after, 442
clinical trials of, central pathology review for, 307
cranial, late effects of, magnetic resonance imaging/angiography of, 1846
endocavitary, for rectal cancer, 967
for endometrial cancer, 2044
leukemia after, 644
for head and neck cancer, 319, 1653
for inflammatory breast cancer, failure of, 2286
for invasive cervical cancer, 1934
¹³¹I-lipiodol, vs. epirubicin-lipiodol, for hepatocellular carcinoma, 2202
for lung cancer, with/without chemotherapy, 779
for malignant glioma, 307
for nonsmall cell lung cancer
with chemotherapy, 530 (letter)
with/without chemotherapy, 593
for prostate cancer, detection of residual disease after, 1682 (letter)
for recurrent brain metastases, in lung cancer, 765
for small cell lung cancer, 406
for vulvar cancer, 2159
- Radical cystectomy, for superficial bladder cancer, 633
- Radical lymph node dissection, Japanese-type, for gastric cancer, 1302
- Radical prostatectomy
distant metastases after, without prostate-specific antigen elevation, 2530
for high-grade cancer, survival after, 2535
indications for, 1682 (letter)

- Radioimmunoassay, for plasma glutathione S-transferase-pi, in gastrointestinal cancer, 1363
- Radioimmunodiagnosis, of ovarian cancer, 2016
- Radioimmunotherapy, for ovarian cancer, 2016
- ras* p21
- in colorectal cancer, 201
 - in nonsmall cell lung cancer, 2457
 - in papillary thyroid cancer, prognosis and, 1643
- Recombinant human erythropoietin, for cancer-associated anemia, 2319
- Rectal cancer. *See also* Colorectal cancer
- distal spread of, surgical margins and, 388
 - endocavitary radiotherapy for, tumor ulceration and, 967
 - pulmonary metastases in, surgery for, 393
- Relative survival rate, 1687
- Renal cell carcinoma
- interleukin-2 for
 - myositis and, 1219
 - with/without lymphokine-activated killer cells, 824
 - interleukin-4 for, 1629
 - nuclear grading of, prognosis and, 2543
 - nuclear morphometry in, prognosis and, 1440
 - polyethylene glycol-modified interleukin-2 for, 687
 - prognostic factors in, 2543, 296, 1440
 - screening for, urinary beta-glucuronidase in, 473
 - serum acute phase reactants in, prognosis and, 1428
- Renal clear cell sarcoma, after in vitro fertilization, 2372
- Renal toxicity
- ifosfamide, 2557, 497
 - methotrexate, carboxypeptidase-G₂ rescue in, 521
- Renal tumors, papillary, 669
- Reproductive status
- breast cancer prognosis and, 531 (letter)
 - epithelial ovarian cancer and, 284
- Retinoic acid
- for acute promyelocytic leukemia, cost-benefits of, 603
 - for germ cell tumors, 680
- RET mutations, in medullary thyroid cancer, 479
- Reverse-transcriptase polymerase chain reaction, for breast cancer micrometastases, 533 (letter)
- Rhabdomyolysis, after biochemotherapy, 678
- Rhabdomyosarcoma
- childhood, long-term survivors of, second malignancy in, 1860
 - classification of, 1073
- S**
- Saporin toxins, for ovarian cancer, 79
- Sarcoma
- classification of, 1073
 - clear cell, of kidney, after in vitro fertilization, 2372
 - Ewing's, of pelvis, surgical indications for, 1388
 - soft tissue
 - of flexor fossae, prognostic factors in, 1398
 - p53 in, 1187
 - paclitaxel for, 2248
- SC-1 antibody-induced apoptosis, of gastric carcinoma cells, 550
- Schwannoma, cutaneous plexiform, neurofibromatosis type 2 and, 1181
- Scleroderma, cancer incidence in, 910
- Scleroderma-like lesions, of lower extremity, docetaxel and, 110
- Screening
- for breast cancer
 - benefits of, 1579
 - Canadian National Breast Cancer Screening Study for, 2107
 - controversies in, 2064
 - psychosocial issues in, 2133
 - training module for, 2125
 - in women under 50, 1579, 1679 (letter), 2064, 2097
 - for cervical cancer
 - future directions in, 1919
 - psychosocial issues in, 2133
 - communicating results of, 167
 - for esophageal cancer
 - by chromoendoscopy, 919 (editorial)
 - by endoscopy and iodine staining, 928
 - for neuroblastoma, 695, 2363
 - for ovarian cancer
 - algorithm for, 2004
 - psychosocial issues in, 2133
 - tumor markers in, 2092
 - ultrasonography in, 1214, 2011, 2086
 - for prostate cancer
 - European randomized study of, 129
 - in Japan, 463
 - for renal cell carcinoma, urinary beta-glucuronidase in, 473
- SEER Program (National Cancer Institute), case reporting completeness in, 2343
- Seminoma, galactosylgloboside in, metastasis and, 1043
- Serine proteases, in gastric cancer, 367
- Serum acute phase reactants, in renal cell carcinoma, prognosis and, 1428
- Serum basic fibroblast growth factor, in men with/without prostate cancer, 2304
- Serum markers. *See* Tumor markers
- Sexual function, after gynecologic cancer, 2117
- Sho-saiko-to (TJ-9), for hepatocellular carcinoma prevention, 743
- Sialic acid residues, in colorectal cancer, 727
- Sialosyl Tn antigen, in advanced gastric cancer, prognosis and, 1529
- Silicone breast implants, in breast reconstruction, 2070
- Sinonasal psammomatoid ossifying fibromas, 1155
- Sinuses, paranasal, chondrosarcoma of, 1550
- Skin, cutaneous plexiform schwannoma of, neurofibromatosis type 2 and, 1181
- Skin cancer
- multiple, impaired cell-mediated immunity and, 228
 - in systemic sclerosis, 910
- Smoking, secondary pancreatic cancer and, 589
- Social support, breast cancer survival and, 631
- Socioeconomic status
- cervical cancer survival and, 2518
 - gynecologic cancer and, 2176

Soft tissue sarcoma

- classification of, 1073
- of flexor fossae, prognostic factors in, 1398
- p53 in, 1187
- paclitaxel for, 2248

Soluble interleukin-2 receptor alpha, in benign/malignant ovarian cancer, 1615

S-phase fraction, in non-Hodgkin's lymphoma, prognosis and, 1059

Sphenoid sinus, chondrosarcoma of, 1550

Spinal metastases, from solid tumors, survival and, 1453

Spindle cell tumor of larynx, inflammatory myoblastic tumor simulating, 2217

Spiral computed tomography, of focal hepatic tumors, 2434

Spitz-like childhood tumors, atypical, 1833

Squamous cell carcinoma

esophageal

- early stage, prognosis of, 178
- MIB-1 proliferation index in, 358
- of head and neck. *See* Head and neck cancer
- of lung, mean nuclear volume in, prognosis and, 797
- oral

human papillomavirus in, 1513

p53 in, 1513

proliferating cell nuclear antigen in, 1513

vulvar, cytokeratin subtypes and involucrin in, 638

Squamous cell carcinoma antigen

in cervical cancer, 807

in hypopharyngeal/laryngeal cancer, 758

Squamous epithelial lesions, of cervix, treatment of, 1928

Staging

of cervical cancer, Bethesda system for, 1914

of endometrial cancer, 2041

of prostate cancer, mean nuclear volume in, 91

Stem cell support. *See also* Bone marrow transplant

with high-dose chemotherapy, hemolytic uremic syndrome after, 2338

Steroid hormones, sensitivity to, in endometrial cancer, epidermal growth factor and, 2524

Stomach. *See under* Gastric

Suramin, for prostate cancer, 453

Surgery. *See also specific sites and types*

for cervical cancer, 1019

for Ewing's sarcoma of pelvis, indications for, 1388

for gallbladder cancer, survival and, 1145

for melanoma, 2384 (letter)

minimally invasive, in children, 121

for pulmonary blastoma, with chemotherapy, 1537

secondary cytoreductive, for recurrent ovarian cancer, 1606

for Stage C prostate cancer, with radiotherapy, 1621

for submucosal gastric cancer, 935

for vulvar cancer, 2159

Survival rate, relative, 1687

Systemic sclerosis, cancer incidence in, 910

T

Tamoxifen

for endometrial cancer, 2044

endometrial insulin-like growth factor and binding protein mRNA and, 1406

tibial artery thrombosis and, 1006

Taxol. *See* Paclitaxel

T-cell acute lymphoblastic leukemia, mitoxantrone for, 339

T-cell lymphoma. *See also* Lymphoma

mitoxantrone for, in children, 339

nasal

p-glycoprotein/MDR1 in, 2351

as proliferation of large granular leukocytes with CD3 phenotype, 537 (letter)

Tertiary care center ICU, advance directives in, 1268

Testicular germ cell tumors, *all-trans*-retinoic acid for, 680

Testicular seminoma, galactosylgloboside in, metastasis and, 1043

Thiotepa, multiple-cycle high-dose, with hematopoietic progenitor cells, 860

Thomsen-Friedenreich-related antigens, in colorectal cancer, 1700

Thoracotomy, for pulmonary metastases, in rectal cancer, 393

3-D computer imaging, of intraductal extension of breast cancer, 32

Thrombosis, tibial artery, tamoxifen and, 1006

Thrombospondin, in upregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1, in breast cancer, 998

Thyroid cancer

follicular, in Chernobyl children, 900

MDM2 expression in, 314

medullary, RET mutations in, 479

papillary

chronic lymphocytic thyroiditis and, 2312

oncoproteins in, prognosis and, 1643

Thyroiditis, chronic lymphocytic, thyroid papillary carcinoma and, 2312

Thyroid tumors, in Chernobyl children, 900

Tibial artery thrombosis, tamoxifen and, 1006

Tissue inhibitor of metalloproteinase-1, vs. matrix metalloproteinase, in gynecologic cancer, 2565

Tissue polypeptide antigen, in cervical cancer, 807

TJ-9 (Sho-saiko-to), for hepatocellular carcinoma prevention, 743

T lymphocytes, in advanced cervical neoplasia, 1411

Tomography, positron emission, of central neurocytoma, 1224

Total parenteral nutrition, methionine-deprived, protein turnover and, 1275

Transcatheter arterial embolization, for hepatocellular carcinoma, portal circulation after, 736

Transferrin receptor, in lung cancer, 20

Transforming growth factor-beta 1, in upregulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-1, in breast cancer, 998

Transplant

bone marrow

for advanced neuroblastoma, 1295 (letter)

with high-dose chemotherapy, hemolytic uremic syndrome after, 2338

oral mucositis in, laser therapy for, 2550

- prochlorperazine-based vs. metoclopramide-based antiemetic therapy in, 2330
 - hepatic, Epstein-Barr virus-related lymphoproliferative disorders after, 1344
 - Transvaginal sonography, in ovarian cancer screening, 2011, 2086
 - Treatment decisions
 - communication of to patient, 167
 - n intensive care, 2171
 - Treatment withdrawal, advance directives for, in cancer center ICU, 1268
 - trk A* gene, in neuroblastoma, 1086
 - Tropisetron, vs. ondansetron and granisetron, for nausea and vomiting, 343
 - True histiocytic lymphoma, transformation of chronic lymphocytic leukemia to, 609
 - Tumor angiogenesis, in lung adenocarcinoma, metastasis and, 915 (letter)
 - Tumor invasion, molecular genetics and, 1874
 - Tumor markers. *See also specific markers*
 - in colonic cell line, 195
 - in lung cancer, 1166
 - in ovarian cancer screening, 2092
 - pretreatment, in cervical cancer, 807
 - Tumor registries, follow-up methods of, 880
 - Tumor suppressor genes
 - in endometrial cancer, 2034
 - in ovarian cancer, 1992, 1998
 - Tumor viruses, pituitary tumors and, 490
 - Typhoid, gallbladder cancer and, 1747
- U**
- Ultrasonography
 - of breast cancer, 627
 - color Doppler
 - in assessment of radiation therapy, for cervical cancer, 67
 - in ovarian cancer screening, 1214
 - in ovarian cancer screening, 1214, 2011, 2086
 - United States-Italy Workshop on Molecular Genetics of Cancer, 1868, 1869, 1874, 1878
 - Urinary beta-glucuronidase, in urinary tract cancer screening, 473
 - Urokinase-type plasminogen activator
 - in breast cancer, 998
 - in gastric cancer, 367, 941
 - Urothelial cancer. *See also* Bladder cancer
 - aromatic amines and, 1445
 - cisplatin, carboplatin, and methotrexate for, 1797
 - Uterine cancer. *See also* Gynecologic cancer
 - bcl-2 expression in, 2297
 - risk of, familial ovarian cancer and, 1416
 - Uveal melanoma, metastatic to liver, treatment of, 1665

Authors' Index—Volume 76

A

Abbruzzese, J. L., 1709
 Abe, R., 32
 Acevedo, H. F., 1467
 Adamson, P. C., 521
 Adler, C. P., 1176
 Ahmad, Y. H., 869
 Ahmed, S., 268
 Ahsan, H., 589
 Aihara, T., 1779
 Akaogi, E., 895
 Akazawa, K., 1313
 Åkervall, J. A., 853
 Akie, K., 2457
 Akslen, L. A., 1643
 Albitar, M., 985
 Albo, D., 998
 Albonico, G., 2510
 Alessandro, R., 1874
 Alkalay, D., 1829
 Allen, K., 243
 Al-Sedairy, S., 314
 Al-Shaikh, R., 1388, 1398
 Altermatt, H. J., 4
 Amberson, J. B., 268
 Amemiya, A., 1513
 Anderlini, P., 678
 Andersen, A., 442
 Andersen, J. A., 250
 Ando, T., 2449
 Andreeff, M., 1564
 Andrews, W. S., 1481
 Ang, K. K., 319
 Ansink, A., 638
 Anwar, N., 1245
 Aoyama, T., 91
 Applebaum, H., 121
 Aranda, E., 559
 Arase, Y., 1139
 Arbit, E., 765, 1453
 Armitage, N. C. M., 383
 Arnoletti, J. P., 998
 Arriagada, R., 779, 2260, 2286
 Arseneau, J., 1591
 Ashley, J. M., 2491
 Asmar, L., 1073
 Asou, N., 602
 Atienza, D. M., 2485
 Atkinson, D., 210

Auchincloss, S. S., 2117
 Averette, H. E., 1096, 1885, 1978
 Avril, A. R., 1126
 Avvento, L., 1330
 Ayala, A. G., 223
 Azizi, E., 1571

B

Baars, J. W., 2338
 Baer, S. C., 2242
 Baergen, R. N., 1545
 Baert, L., 1621
 Bagga, D., 2491
 Bahado-Singh, R. O., 67
 Bailes, J. S., 1886
 Baines, C. J., 2107
 Bajada, C. L., 1069
 Bajorin, D. F., 824
 Balcerzak, S. P., 2248
 Baldus, S. E., 954
 Balis, F. M., 521, 2557
 Barasch, A., 2550
 Bardi, G., 250
 Barnard, R. J., 2491
 Barnhill, R. L., 1833
 Barni, S., 1694
 Bartolozzi, C., 1737
 Basukas, I. D., 296
 Bast, R. C., Jr., 1615, 2004, 2092
 Battafarano, D. F., 110
 Bauernhofer, T., 2319
 Bauknecht, T., 57
 Baxevanis, C. N., 1253
 Bazan, V., 1757
 Becker, E., 875
 Bécouarn, Y. H., 1126
 Bedikian, A. Y., 1665
 Behrendt, H., 339
 Beinbauer, A., 2319
 Beitz, J. G., 79
 Bell, J. M., 1853
 Bell, M. C., 1948
 Belpomme, D., 779
 Beltangady, M. S., 1073
 Ben-Ari, G., 215
 Benedetti, J., 1233, 2248
 Benhamou, E., 2260
 Benhamou, S., 2260
 Benjamin, R. S., 1476, 1665
 Benninger, M. S., 1655
 Berchuck, A., 1615, 2034
 Berek, J. S., 2092
 Berenberg, J. L., 715
 Berg, G. E. B., 1261
 Bergan, R. C., 453
 Berger, D., 1187
 Bergot, C., 1559
 Berkowitz, R. S., 2079
 Berlin, J. A., 1747
 Berns, J. S., 497
 Bernstein, M., 2363
 Beroukas, C., 1253
 Bevilacqua, G., 1737
 Bhattacharya, B. N., 1145
 Bhattacharya, S., 2202
 Bianco, A. R., 1772
 Bicher, A., 116
 Biondi, E., 1585
 Bisceglia, M., 2217
 Bismuth, H., 1344
 Bitsura, J. M., 46
 Bittinger, F., 922
 Blanco, E., 559
 Blaney, S., 2557
 Blatt, J., 890
 Bloch, A. R., 1245
 Blume, K. G., 860
 Blumenstein, B. A., 2304
 Boes, G. H., 333
 Boice, J. D., Jr., 442
 Bokey, L., 564
 Bollschweiler, E., 178
 Bonfrer, J. M. G., 807
 Bonner, J. A., 406
 Bonsib, S. M., 669
 Boop, F. A., 1853
 Bordin, G., 1814
 Bornstein, A., 1571
 Borrone, C., 1662
 Bosl, G. J., 680
 Bossolt, K., 268
 Bostwick, D. G., 1035, 1422
 Botti, G., 1585
 Bouchier-Hayes, D., 2418
 Boyd, J., 2034
 Boyd, S. B., 1655
 Boyd, S. D., 833
 Brackrock, S., 727
 Brady, L. W., 2143
 Brambilla, C., 1540

- Brambilla, E., 1540
 Brasseur, L., 2375
 Bratton, J., 268
 Brawer, M. K., 2304
 Bredbacka, Å. B., 67
 Brehm, G., 1460
 Breitenecker, G., 1786
 Brem, S., 709
 Brennan, M. F., 1671
 Brenner, H., 215, 1571
 Bretel, J.-J., 2260
 Bretheau, D., 2543
 Brinton, L. A., 1888
 Brisson, J., 631
 Brisson, L., 2363
 Broendstrup, O., 1809
 Broholm, H., 1809
 Bronte, V., 1878
 Brossard, J., 2363
 Brouet, J.-C., 1559
 Brower, S. T., 268
 Brown, B. W., 1709
 Brown-Shimer, S., 201
 Brunet, R. C., 1126
 Brusco, C., 268
 Buckner, J. C., 96
 Budillon, A., 1869
 Budzilovich, G. N., 840
 Bulfill, J. A., 2389
 Burch, P. A., 96
 Burdach, S. E. G., 510
 Burke, T. W., 116
 Burns, P., 1330
 Burris, H. A., 110
 Burt, M., 765
 Bussi eres, E. J., 1126
 Buzaid, A. C., 678
 Byers, R. M., 319
 Byrne, T. D., 2363
 B  k-Hansen, T., 797
- C**
 Calabresi, P., 135
 Cannata, G., 1821
 Cantoni, A., 593
 Cao, Y., 1700
 Capasso, I., 1585
 Capria, A., 1737
 Caramella, D., 1737
 Cardin, R., 367
 Carlomagno, C., 1772
 Carlson, E. R., 1655
 Carlson, R. W., 259
 Carney, W. P., 201
 Carrai, M., 1737
 Carraro, P., 367
 Carrasco, C. H., 1665
 Carrato, A., 559
 Carriaga, M. T., 237
 Cassaro, M., 376
 Castiglioni, A., 998
 Cataldo, P. A., 967
 Catane, R., 2181
 Cavalieri, J., 2427
 Cavalleri, E., 2291
 Cavazzana, A. O., 1073
 Cayouette, M. C., 2427
 Cerroni, L., 26
 Cervantes, A., 559
 Chabot, J. R., 967
 Chambers, E. J., 1846
 Chan, A. C. L., 658
 Chan, J. K. C., 413, 1689
 Chan, K. W., 658
 Chan, W. K., 2186
 Chang, V., 1283
 Chang, Y., 2004
 Changchien, C. R., 1724
 Chao, N. J., 860
 Chapman, M. A. S., 383
 Chapuis, P. H., 564
 Charvolin, P., 779
 Chasen, M. H., 2230
 Chastang, C., 779
 Chaves, P. P., 1522
 Chayama, K., 1139
 Chen, D. K., 840
 Chen, J. S., 1724
 Chen, J.-T., 291
 Chen, K. Y., 2186
 Chen, P., 674
 Chen, S.-C., 833, 1621
 Chen, S. Y., 2186
 Cheney, C., 1814
 Cherny, N. I., 2181
 Cherny, N. J., 1283
 Cheville, J. C., 1035, 1422
 Chi, K. H., 2186
 Chiba, I., 1513
 Childers, J. M., 2113
 Chmiel, J. S., 1934, 1948
 Cho, J. M., 2434
 Choi, B. I., 2434
 Choi, D. S., 2434
 Chow, J. H.-S., 1336
 Chowhan, N., 1330
 Christiansen, G., 479
 Chucrallah, A. E., 985
 Clark, J. M., 20
 Clark, R. A., 774
 Claudiani, F., 1662
 Claus, E. B., 1998
 Cleri, L. B., 774
 Clive, J., 2550
 Clive, R. E., 1934, 1948
 Cobau, C. D., 1731
 Cody, H. S., III, 1579
 Cohen, C. J., 2044
 Cohen, R. M., 497
 Colditz, G. A., 284
 Colleau, S. M., 2375
 Colomer, A., 479
 Connolly, J. L., 1
 Connor, J. L., 572
 Conte, P. F., 1737
 Contesso, G., 2260
 Cook, J., 79
 Cooper, J. S., 328
 Cooper, M. R., 453
 Copeland, B., 1814
 Coplin, M. A., 1325
 Corn, B. W., 163
 Cortes, J. E., 2393
 Coulange, C., 2543
 Couzi, R., 2059
 Cowan, B., 2075
 Cox, C. E., 243
 Cozzi, P. J., 501
 Cravo, M. L., 1522
 Creagan, E. T., 406
 Creasman, W. T., 2075
 Crockaert, F., 1166
 Crosignani, P., 1601
 Crowley-Nowick, P., 1411
 Cruz-Hernandez, J. J., 559
 Curran, W. J., Jr., 163, 307
 Cuy as, J. M., 758
 Czarnecki, D., 228
 Czerniak, B., 223
- D**
 Dal Pino, D., 2291
 Dalton, R. B., 961
 D'Ambrosio, J. A., 2550
 D  mmrich, J., 296, 550
 Dardanoni, G., 1757
 Darlington, G. A., 644
 Dautzenberg, B., 779
 Davis, F. G., 875
 Davis, G. L., 661
 Davol, P., 79
 Dawson, D. B., 1481
 Dawson, N. A., 453
 Dayal, Y. Y., 1731
 DeAngelis, L. M., 232
 De Bernardi, B., 1662
 Dedoussis, G. V. Z., 1253
 de Fromont, M., 2543
 de Glas-Vos, C. W., 2338
 Defesus, Y., 116
 de Koning, H. J., 129
 De Laurentiis, M., 1772
 Deligdisch, L., 1027
 Dell'Aquila, M., 1545

- De Marco, M., 1585
 Denis, L. J., 129
 Denk, H., 1302
 Dent, O. F., 564
 De Placido, S., 1772
 DePriest, P. D., 1992, 2086
 Deschênes, L., 631
 Deshmukh, N., 1006
 Devaney, K., 2217
 Dewar, J. A., 2260
 Diamantis, P. M., 1715
 Dick, R., 2202
 Dickman, P. S., 890
 Dilhuydy, J.-M. A., 1126
 Dillioğlu, Ö., 2530
 Dillon, P. W., 121
 Di Mario, F., 376
 DiMassimo, B. I., 700
 DiSaia, P. J., 2075
 Dmitrovsky, E., 680
 Docherty, A. J., 700
 Doi, O., 1368
 Donahue, B. R., 328
 Dor, J., 2372
 Dorey, F. J., 1388, 1398
 Dorta, J., 559
 Dosaka-Akita, H., 2457
 Doyle, T. J., 1655
 Dragovic, J., 1655
 Duchateau, J., 1166
 Duncan, A. W., 1846
 Duncan, L. J., 2266
 Dundore, P. A., 1035, 1422
 Dupont, W. D., 1197
 Dusheiko, G. M., 2202
 Dutkowski, P., 922
 Díaz-Rubio, E. on behalf of the Spanish Cooperative Group for Gastrointestinal Tumor Therapy (TTD), 559
- E**
 Eagan, R. T., 406
 Eckardt, J. J., 1388, 1398
 Edraki, B., 1987
 Edwards, M., 674
 Edwards, R. P., 1411
 Egawa, S., 463
 Eilber, F. R., 1388, 1398
 Einhorn, N., 2004
 Einstein, A. J., 1027
 Eisenkop, S. M., 1606
 El Bolkainy, N., 1245
 El Chaarani, B., 1166
 Elder, D. E., 2242
 Emslie-Smith, A., 1219
 Endo, M., 736
 Endo, Y., 941
- Engel, A. G., 1219
 Englund, R., 501
 Engstrom, P. F., 1731
 Enomoto, K., 2504
 Enomoto, N., 2211
 Ensley, J., 1233
 Ermilova, V. D., 2524
 Esrig, D., 833
 Esteva-Lorenzo, F. J., 1219
 Evans, H. L., 319
 Evans, R. G., 406
 Ewer, M. S., 1268
- F**
 Fabre, C., 779
 Fagin, J. A., 900
 Fan, K.-C., 1363
 Fan, S. T., 2443
 Farid, N. R., 314
 Farinati, F., 367, 376
 Farnan, N. C., 307
 Farrow, G. M., 1035, 1422
 Feig, S. A., 2097
 Fenton, R. G., 1219
 Ferenczy, A., 1928
 Ferit, T., 1829
 Ferman, J.-P., 1559
 Fernández-Martos, C., 559
 Ferretti, S., 2510
 Fetsch, J. F., 2253
 Fidalgo, P. O., 1522
 Fidias, P., 1377
 Fields, A. L., 2028
 Figg, W. D., 453
 Figols, J., 1181
 Finn, L. S., 890
 Fiore, J., 1330
 Fischbach, A. J., 307
 Fischer, C., 1051
 Fischer, R., 954
 Fisher, S., 497
 Flannery, J. T., 442
 Fleischli, M., 1833
 Fleming, T. R., 715
 Flotte, T. J., 1833
 Foley, K. M., 1283
 Folsom, A. R., 275
 Fontaine, A., 2375
 Fontaine, F., 2286
 Ford, M. B., 2125
 Foreman, N. K., 1846
 Forman, A. D., 1804
 Formenti, S., 1621
 Forscher, C. A., 1388, 1398
 Fossella, F. V., 2230
 Fowler, C. B., 1155
 Frackelton, A. R., Jr., 79
 Frager, G., 1283
- Francis, I. R., 1120
 Franklin, J., 1245
 Frankowski, R. F., 46
 Franquin, J.-C., 2550
 Freeman, J., 1621
 Freeman, J. A., 833
 Freilich, R. J., 232
 Fremgen, A., 1948
 Fremgen, A. M., 1934
 Friedman, J., 1571
 Friedman, R. L., 1606
 Frisch, J., 510
 Frisch, M., 106
 Fritz, E., 2319
 Frohmüller, H. G. W., 296
 Fruechticht, W., 727
 Frytak, S., 406
 Fujigaki, Y., 895
 Fujikawa, K., 91
 Fujimoto, J., 2449
 Fujimura, T., 941
 Fujinaga, K., 1513
 Fujino, M., 2457
 Fujisawa, T., 2464
 Fujiwara, H., 1591, 1902
 Fujiwara, M., 2312
 Fukuda, H., 101
 Fukuda, T., 972
 Fukumoto, M., 2351
 Fukushi, Y., 1043
 Fukushima, S., 358
 Fukushima, T., 32, 895
 Fukuzawa, M., 695
 Fukuzawa, S., 1790
 Fuller, A. F., Jr., 1209
 Funaoka, K., 1513
 Funkhouser, E. M., 1116
 Furukawa, K., 2449
- G**
 Gaarenstroom, K. N., 807
 Gabbert, H. E., 720, 922
 Gajalakshmi, C. K., 644
 Galicich, J. H., 765, 1453
 Gallinger, S., 187
 Gallion, H. H., 650, 1992, 2086
 Gallo, A., 1019
 Gallo, C., 1772
 Gamel, J. W., 1009
 Garaventa, A., 1662
 Garb, J. L., 967
 García-Conde, J., 559
 Garden, A. S., 319
 Garrett, C. T., 86
 Gaspar, L. E., 307
 Gattorno, M., 1662
 Gautam, S., 20
 Gebbia, N., 1757, 1821

- Gebbia, V., 1821
 Geffen, D. B., 1829
 Geffrey, S. P., 2491
 Gehan, E. A., 1073
 Gelder, M. S., 2171
 Genta, R. M., 1150
 Gerber, H. A., 4
 Gerdes, A.-M., 250
 Gershenson, D. M., 116
 Gershtein, E. S., 2524
 GETCB (Groupe d'Etude et de
 Traitement des Cancers
 Bronchiques), 779
 Geyer, C., Jr., 2275
 Ghavimi, F., 1860
 Giaccon, G., 1694
 Gil, J., 1027
 Gilbert, C. J., 2330
 Gilchrist, G. S., 2471
 Gitsch, G., 1786
 Globits, S., 1356
 Glonek, T., 1715
 Gnepp, D. R., 900
 Göbel, U., 510
 Goddard, P. R., 1846
 Goff, B. A., 1209
 Goffinet, D. R., 259
 Goldberg, G. L., 2028
 Goldberg, R. M., 961
 Goldenberg, S. L., 626
 Goldstein, D. P., 2079
 Goldwasser, B., 1440
 Gollard, R., 1814
 Golledge, J., 1051
 Gonzalez-Crussi, F., 1073
 Gonzalez-Mancha, R., 559
 Goodacre, A. M., 609
 Goodman, Z. D., 579
 Göppinger, A., 57
 Gordon, P. B., 626
 Goseki, N., 736
 Goshen, E., 215
 Gossart, B., 1166
 Gralla, R. J., 774
 Granick, M. S., 998
 Grankvist, K., 1435
 Grayhack, J. T., 2535
 Greipp, P. R., 1059
 Grenman, S. A., 67
 Gridley, G., 910
 Griem, K. L., 2497
 Griffin, T. W., 20
 Grigioni, W. F., 367
 Grimson, R., 700
 Grönroos, M., 1214
 Grosen, E. A., 2075
 Groshen, S., 833, 1621
 Gross, H. M., 1709
 Guera, D., 1027
 Guérin, R. A., 779
 Guido, M., 376
 Guillem, J., 1715
 Gula, M. J., 890
 Guy, J. T., 715
H
 Haase, G. M., 121
 Habermann, T. M., 1059
 Hachitanda, Y., 2363
 Haensch, W., 1700
 Hagag, N., 1330
 Haghighat, A., 497
 Haghighi, P., 1545
 Haida, T., 1715
 Hakomori, S., 1043
 Hale, R. J., 1591
 Haller, D. G., 1731
 Halling, K. C., 1765
 Hallum, A. V., III, 2113
 Hamada, K., 72
 Hamoudi, A. B., 1073
 Han, J. K., 2434
 Han, J.-S., 195
 Han, M. C., 2434
 Hanisch, F.-G., 954
 Hankey, B. F., 442, 2343
 Hankinson, S. E., 284
 Hara, Y., 2312
 Harada, M., 2457
 Hardcastle, J. D., 383
 Harihara, S., 743
 Harms, D., 1073
 Harner, S. G., 4
 Harpole, D. H., Jr., 787
 Harris, J. R., 1
 Hart, A. A. M., 807
 Hartmann, L. C., 96
 Hartsell, W. F., 2497
 Hartsock, R. J., 1467
 Hasegawa, T., 618
 Hashimura, M., 2297
 Hashimura, T., 1790
 Hatazawa, J., 1224
 Hatch, K. D., 2113
 Hayashi, A., 393
 Hayashida, M., 928
 Hayes, R. L., 840
 Headlee, D. J., 453
 Heber, D., 2491
 Heegaard, S., 1809
 Heffess, C. S., 900
 Heffner, D. K., 1155
 Heilmann, H.-P., 2143
 Heim, S., 250, 853
 Heintz, A. P. M., 638
 Heitz, P. U., 479
 Heller, G., 1860
 Helmerhorst, T. J. M., 807
 Helzlsouer, K. J., 2059
 Henderson, M. M., 2053
 Hennekens, C. H., 284
 Henrik-Nielsen, R., 797
 Henriques, U., 797
 Henson, D. E., 237, 1687
 Hentschel, P., 1330
 Hepburn, L. M., 1120
 Herget, G. W., 1176
 Herndon, J. E., II, 787
 Herszényi, L., 367
 Hetherington, M. L., 521
 Hickok, J. T., 343
 Hicks, M. L., 2176
 Hiesiger, E. M., 840
 Higashino, M., 358
 Higashiyama, M., 1368
 Hiller, E., 1460
 Hilsenbeck, S., 1978
 Hilson, A. J., 2202
 Hino, K., 1352
 Hinze, R., 1187
 Hiort, O., 479
 Hirano, S., 463
 Hirohata, T., 1445
 Hirokado, K., 463
 Hirose, T., 4, 618
 Hiroshima, K., 2464
 Hiroumi, H., 2457
 Hirsch-Ginsberg, C., 992
 Hittelman, W. K., 1956
 Hiyama, E., 1086
 Hizawa, K., 618
 Ho, E. S.-C., 291
 Ho, K.-J., 473
 Ho, P. T. C., 2557
 Ho, Y.-S., 1724
 Hobbs, K. E., 2202
 Hochster, H. S., 840
 Hoffman, M. A., 2237
 Hofmockel, G., 296
 Holcomb, G. W., III, 121
 Holowaty, E. J., 644
 Hölscher, A. H., 178
 Homesley, H. D., 2159
 Hommel, G., 720
 Honchel, R., 1765
 Hong, W. K., 919, 1956, 2230
 Horowitz, I. R., 2518
 Hoshi, K., 32
 Houlihan, M. J., 1491
 Houston, G. D., 1155
 Hoyle, C. F., 860
 Hsu, K. C., 1724
 Huang, Y.-C., 1363
 Huh, Y. O., 985, 1564

Hui, P.-K., 413
 Huiras, C. M., 1537
 Hunter, D. J., 284
 Hunter, S. H., 2518
 Hurdebourcq, M., 779
 Hurteau, J. A., 1615
 Hussain, M., 1233
 Hussain, S. S., 314
 Huston, B. J., 669
 Hutchins, L. F., 715
 Hutter, R. V. P., 2266
 Hymes, K. B., 840

I

Iavorone, A., 674
 Icenogle, J. P., 2518
 Ichikura, T., 935
 Ida, N., 1086
 Idvall, I., 250
 Iino, S., 1352
 Iishi, H., 750
 Ikeda, E., 1132
 Ikeda, K., 1139
 Ikeda, T., 2504
 Ikenberg, H., 57
 Iketani, H., 72
 Imaoka, S., 1779
 Imura, K., 695
 Inaji, H., 1779
 Indelli, M., 2510
 Ingham, J. M., 1283
 Ingria, F., 1757
 Inoue, Y., 72
 Iscovich, J., 1571
 Ishak, K. G., 579
 Ishibashi, N., 1275
 Ishii, H., 928
 Ishii, S., 2504
 Ishikawa, H., 2565
 Ishikawa, O., 750
 Isomoto, H., 388, 393
 Israel, M. A., 674
 Itasaka, H., 399
 Itnyre, J. H., 1416
 Itoh, H., 941
 Itoh, T., 91
 Itoh, Y., 1224
 Ivanyi, D., 638
 Iwamoto, Y., 972
 Iwasa, Y., 429
 Izraeli, S., 2557

J

Jacobs, I. J., 1615
 Jacobsen, G. R., 1655
 Jaffe, E. S., 1245
 Janicek, M. F., 1096
 Janik, J. E., 1219

Japan Adult Leukemia Study Group,
 602

Jarosinski, P., 2557
 Jatzko, G. R., 1302
 Jeffrey, S., 259
 Jensen, R. A., 1197
 Jensen, S., 674
 Jin, Y., 853
 Jishi, M. F., 1416
 Joensuu, H., 1201
 Johansson, B. R., 1261
 Johnson, F. E., 1325
 Johnson, K. A., 201
 Johnson, P. J., 1336
 Johnson, P. R., 2518
 Johnston, D., 223
 Jones, D. V., Jr., 1709
 Jones, H. W., III, 1914
 Jones, M. A., 1209
 Jones, W. B., 1934, 1948
 Josephs, W., 510
 Juillard, G. J. F., 1069
 Juliusson, G., 423
 Jürgens, H., 510

K

Kaibara, A., 1275
 Kainz, C., 1786
 Kaji, M., 941
 Kakegawa, T., 388, 393, 1275
 Kamby, C., 1797
 Kamiya, H., 86
 Kan, N., 429
 Kaneko, M., 895
 Kannagi, R., 429
 Kantarjian, H. M., 985, 992, 1564, 2393
 Kaplinsky, C., 2372
 Kapoor, V. K., 1145
 Kappeler, A., 2319
 Karlan, B. Y., 2011
 Karsten, U. R., 1700
 Kasimos, J. N., 1715
 Kassis, A. I., 2016
 Katsura, Y., 358
 Katz, J. A., 1481
 Kaushik, S. P., 1145
 Kawahara, N., 399
 Kawakami, T., 463
 Kawakami, Y., 2457
 Kawamura, S., 1043
 Kay, T., 228
 Kaye, S., 333
 Keating, M., 992, 1564
 Keeling, J. H., 110
 Kelly, C. M., 1388
 Kenet, G., 2372
 Kenter, G. G., 807
 Kerl, H., 26
 Khan, A., 824
 Khoo, K.-S., 680
 Khorana, S., 1665
 Kiechle-Schwarz, M., 57
 Kiehl, R., 869
 Kihana, T., 72
 Kiilholma, P., 1201
 Kikkawa, F., 2565
 Kikuchi, K., 2504
 Kilpatrick, S. E., 2471
 Kim, B.-G., 814
 Kim, C. Y., 2434
 Kim, J.-H., 814
 Kim, K., 201
 Kim, K.-H., 814
 Kim, S. R., 743
 Kim, Y.-C., 429
 Kimijima, I., 32
 King, J., 572
 Kingma, D. W., 1245
 Kinman, J. L., 1747
 Kinoshita, H., 358
 Kinoshita, I., 2457
 Kinoshita, T., 2504
 Kirkels, W., 129
 Kita, K., 2351
 Kitajima, M., 2504
 Kitamura, T., 750
 Kjellberg, J. L., 880
 Kjellén, E., 853
 Kleer, E., 1422
 Klein, E., 215
 Kleiner, G. J., 2237
 Kleinerman, R. A., 442
 Klemi, P.-J., 1201
 Klimpfinger, M., 1302
 Klingenstein, H. A. G., 1261
 Knapp, R. C., 2004
 Kobashi, Y., 429
 Kobayashi, K., 743
 Kobayashi, M., 1139
 Kobayashi, T., 602
 Kobayashi, Y., 695
 Kodama, K., 1368
 Koechli, O. R., 1978
 Koga, H., 1445
 Kohgo, T., 1513
 Kohlberger, P., 1786
 Kohn, E. C., 1874
 Koida, I., 1139
 Koike, K., 1352
 Koike, M., 736
 Kölbl, H., 1786
 Koller, M. A., 1238
 Komaki, R., 2152, 2230
 Komminoth, P., 479
 Komoto, Y., 695
 Konishi, I., 429

Korenman, S., 2491
 Kornek, G., 1356
 Korse, C. M., 807
 Korzenko, A. V., 900
 Koshiba, K., 463
 Koslow, M., 840
 Kosty, M., 1814
 Kostyleva, O. I., 2524
 Kotoh, S., 1445
 Kowada, M., 1224
 Koyama, H., 1779
 Krasil'nikov, M. A., 2524
 Krause, K. T., 727
 Kris, M. G., 774
 Krook, J. E., 961
 Ku, S., 609
 Kudc, R., 86
 Kulinskáya, E., 228
 Kumada, H., 1139
 Kumar, N. B., 243
 Kumazawa, J., 1445
 Kunz, E. K., 479
 Kuo, S.-H., 473
 Kupchik, H. Z., 201
 Kuriyama, K., 602
 Kurman, C. C., 1615
 Kurokawa, K., 1352
 Kuroki, T., 743
 Kurose, A., 1132
 Kurtin, P. J., 1059
 Kurvinen, K., 1201
 Kurzrock, R., 609
 Kusafuka, T., 695
 Kushi, L. H., 275
 Kushlinsky, N. E., 2524
 Kusnierz-Glaz, C. R., 860
 Kuwao, S., 463
 Kuykendall, K., 1411

L

Laatikainen, T. J., 1406
 Labianca, R., 1694
 Ladekarl, M., 797
 Lager, D. J., 669
 Lai, E. C. S., 2443
 Laippala, P. J., 1214
 Laitt, R. D., 1846
 Lam, K. Y., 658
 Lampe, B., 1978
 Landys, K. E., 1261
 Lane, J. M., 1398
 Lanspa, S., 2427
 Lantuéjoul, S., 1540
 Lappi, D. A., 79
 Lara, P. C., 758
 Larue, F., 2375
 Lau, W.-H., 1689
 Lauria, R., 1772

Lauwers, G., 1715
 Laval-Jeantet, M., 1559
 La Vecchia, C., 2291
 Law, C.-K., 413
 Law, C. K., 2186
 Lawrence, W. D., 2138
 Lawson, J. A., 572
 Leandro, G., 376
 Lebeau, B., 779
 Le Chevalier, T., 779, 2286
 Lechevallier, E., 2543
 Leclerc, J. M., 2363
 Lee, B.-H., 814
 Lee, B. P., 2253
 Lee, E.-D., 814
 Lee, H.-S., 2434
 Lee, J.-H., 814
 Lee, J. S. Y., 2253
 Lee, K.-H., 814
 Lee, M. S., 992
 Lefkopoulou, M., 1731
 Legha, S. S., 678, 1665
 Legnani, W., 1694
 Lei, K. I.-K., 1336
 Leibman, B. D., 2530
 Leitão, C. N., 1522
 Leitch, A. M., 2064
 Leitgeb, C., 2319
 Leitner, S. P., 2266
 Lemieux, B., 2363
 Lencioni, R., 1737
 Leslie, K. O., 20
 Leto, G., 1757
 Leung, M. L., 658
 Levenback, C., 116
 Levery, S. B., 1043
 Levin, B., 1709
 Levin, W., 644
 Levy, L. B., 1709
 Li, C.-H., 1363
 Libshitz, H. I., 437, 803
 Liebrich, W., 1700
 Liengswangwong, V., 406
 Lieskovsky, G., 833, 1621
 Liliemark, J., 423
 Limon, J., 250
 Liotta, L. A., 1868
 Lipera, W., 1330
 Lipsitz, S. R., 1731
 Lisborg, P. H., 1302
 Liu, F.-S., 291
 Ljungberg, B., 1435
 Long, G. D., 860
 Longo, D. L., 1219
 Longo, W. E., 1325
 Lopes, M. B. S., 4
 Lotan, R., 1956
 Lu, Y., 1978

Luce, M. C., 2427
 Ludwig, H., 2319
 Lum, D., 2343
 Lund, B. A., 1550
 Luporini, G., 1694
 Luxton, G., 1621
 Lyman, G. H., 243, 1634
 Lyn, P., 680
 Lynch, C. F., 442
 Lynch H. T., 2427
 Lynch J., 2427
 Lysik, R. M., 700

M

Ma, C.-C., 413
 Macdonald, J. S., 715
 Madajewicz, S., 1330
 Magrath, I., 1245
 Magri, E., 2510
 Mailliard, J. A., 961
 Mäkinen, J. I., 1214
 Makuuchi, H., 928
 Maltinti, G., 1737
 Mandahl, N., 250, 853
 Mandel, M., 2372
 Manning, T., 2275
 Marcantonio, D. R., 803
 Marcial, V. A., 2152
 Mariette, X., 1559
 Marin, J.-L., 2260
 Marincola, F. M., 687
 Marini, G., 1694
 Marino, P., 593
 Marone, A., 1585
 Marsden, H. B., 1073
 Martenson, J. A., 1731
 Martin, R. D., 2125
 Marumo, F., 2211
 Marumo, T., 743
 Maruyama, K., 928
 Massar, C. G., 339
 Matei, D., 1330
 Matias-Guiu, X., 479
 Matsuda, M., 2193
 Matsuda, T., 358
 Matsumata, T., 399
 Matsuura, S., 72
 Matthay, K., 57
 Maunsell, E., 631
 Maurer, H. M., 1073
 Maurer-Schultze, B., 296
 Mavligit, G., 1665
 Mazumdar, M., 824
 McGinn, T., 2427
 McGinnis, L. S., 1104
 McLaughlin, J. K., 910
 McLaughlin, P., 609
 McMurtrey, M. J., 2230

- McPherson, C. P., 880
 McVary, K. T., 2535
 Medalia, O., 1440
 Meier, S., 720
 Melbye, M., 106
 Meller, I., 1829
 Meltzer, S. J., 541
 Menck, H. R., 1096, 1104, 1671
 Meneses, M., 1422
 Merchant, T. E., 1715
 Mertens, F., 853
 Meshulam, C. F., 1453
 Mestecky, J., 1411
 Mettlin, C. J., 1104
 Meye, A., 1187
 Meyer, G. E., 2304
 Meyer, J. S., 1009
 Micaly, B., 2143
 Michils, A., 1166
 Mikuta, J. J., 2041
 Miller, S. M., 167
 Mills, G. B., 1615
 Mineura, K., 1224
 Minsky, B. D., 1715
 Mira, F. C., 1522
 Misra, D. N., 890
 Misset, J.-L., 1344
 Missitzis, I., 1253
 Mitchell, M. F., 1591, 1956
 Mitelman, F., 250, 853
 Mitsui, K., 895
 Miwa, H., 2351
 Miwa, T., 1529, 2193
 Miyamoto, C. T., 2143
 Miyawaki, S., 602
 Miyazaki, I., 941
 Mizuno, K., 2565
 Mizuuchi, H., 86
 Moasser, M. M., 680
 Mody, D. R., 1150
 Moertel, C. G., 961
 Mohler, M., 79
 Moinuddin, S., 1065
 Moll, U. M., 700
 Monfardini, S., 333
 Monna, T., 743
 Montella, M., 1585
 Montemaggi, P., 2143
 Mooi, W. J., 638
 Moore, E. J., 840
 Morabito, A., 1772
 Mori, Y., 86
 Moriya, K., 1352
 Moroni, S., 2291
 Morris, D. L., 501, 572
 Morris, M., 116
 Morrison, W. H., 319
 Morrow, G. R., 343
 Morrow, M., 1113
 Mosharaf, M., 1150
 Moskal, J. R., 709
 Moskovitz, B., 1440
 Motomura, K., 1779
 Motzer, R. J., 680, 824
 Mourad, M., 1245
 Mouriessse, H., 2286
 Mouritzen, C., 797
 Mozes, M., 1829
 Müller, H., 296
 Müller, W., 720
 Müller-Hermelink, H. K., 296
 Müller-Hermelink, H.-K., 550
 Munker, R., 1460
 Muntz, H. G., 1209
 Murao, S., 72
 Murashima, N., 1139
 Murnane, M. J., 201
 Murphy, B. A., 680
 Murphy, G. P., 1104
 Murphy, R. F., 521
 Murphy, W. K., 2230
 Murray, C. L., 880
 Murray, K. J., 307
 Murray Law, T., 824
 Murthy, A. K., 2497
 Müschenich, M., 510
 Muto, M. G., 2016
 Myers, C. E., 453
- ## N
- Naccarato, R., 367
 Nadji, M., 1978
 Nagahara, N., 695
 Nagamatsu, Y., 393
 Nair, P. P., 195
 Naito, S., 1445
 Naka, T., 972
 Nakagawa, H., 541
 Nakagawa, T., 101
 Nakaizumi, A., 750
 Nakamori, S., 1368
 Nakamura, S., 1313
 Nakamura, T., 695
 Nakano, H., 1529, 2193
 Nakayama, M., 695
 Nascimento, A. G., 1035, 1422, 2253
 Nasim, S., 86
 Nass, D., 1571
 Natale, R. B., 715, 2248
 Nativ, O., 1440
 Nawa, A., 2565
 Negri, E., 2291
 Negrin, R. S., 860
 Nelson, D. F., 307
 Nelson, D. L., 1615
 Nelson, J. S., 307
 Nelson, R. L., 875
 Nenci, I., 2510
 Nesbitt, J. C., 437
 Neuburger, M., 1176
 Neugut, A. I., 589
 Neumann, K., 1187
 Neumann, Y., 2372
 Newland, R. C., 564
 Newman, K. D., 121
 Newton, W. A., Jr., 1073
 Ng, I. O. L., 2443
 Ng, M. M. T., 2443
 Nichols, R. D., 1655
 Niederhuber, J. E., 1671
 Nielsen, O. S., 1797
 Nikiforov, Y. Y., 900
 Nikrui, N., 1209
 Ninfo, V., 376, 1073
 Ninomiya, I., 941
 Nishigami, T., 2449
 Nishihara, T., 541
 Nishii, K., 2351
 Nishioka, K., 1956
 Nitti, D., 367
 Noake, T., 1275
 Noguchi, S., 1779
 Nojima, N., 941
 North, P. E., 1238
 Nosaka, T., 736
 Novell, J. R., 2202
 Novotny, J. E., 1537
 Nowels, K. W., 259
 Nuki, K., 2550
 Nyérén, O., 910
 Nzeako, U. C., 579
- ## O
- Oakley-Girvan, I. A., 1416
 O'Brien, M. J., 201
 O'Brien, S., 992
 O'Brien, S. M., 1564
 O'Connell, M., 824
 O'Connor, C. E., 967
 Odicino, F., 2075
 Odze, R. D., 187
 Oefelein, M. G., 2535
 Ogata, T., 895
 Ogawa, T., 1224
 Oh, H., 602
 Ohgashi, H., 750
 Ohly, K. V., 2330
 Ohmori, T., 928
 Ohno, R., 602
 Ohno, T., 2351
 Ohori, M., 463
 Ohtake, T., 32
 Ohwada, H., 2464
 Ohyama, C., 1043

Oishi, N., 715
 Oka, H., 743
 Oka, K., 2351
 Okada, A., 695
 Okamoto, E., 2449
 Okamura, N., 86
 Okayasu, I., 2297, 2312
 Oken, M. M., 1731
 Okuda, S., 750
 Okusa, Y., 935
 Okuyama, K., 928
 Older, S. A., 110
 Olofsson, S. M., 1804
 Olson, K., 674
 Oram, D. C., 1615
 Ordóñez, N. G., 223
 Orikasa, S., 1043
 Oriyama, T., 2449
 Orlando, S. J., 890
 Orringer, M. B., 1120
 Osteen, R. T., 2070
 Osugi, H., 358
 Oue, T., 695

P

Paderanga, D. C., 674
 Page, D. L., 1197
 Pancera, G., 1694
 Pandey, C. M., 1145
 Pandis, N., 250
 Panico, L., 1772
 Paoli, M. D., 367
 Paolicchi, A., 1737
 Papac, R. J., 869
 Papadopoulos, N., 1665
 Papadopoulos, N. G., 1253
 Papamichail, M., 1253
 Parazzini, F., 2291
 Parham, D. M., 1073
 Parham, G. P., 2176
 Park, K.-B., 814
 Park, S.-Y., 814
 Park, T.-W., 1902
 Parker, R. G., 1069
 Parkinson, D. R., 687
 Partridge, E. E., 1411
 Patel, S. R., 1476
 Pavlik, E. J., 2086
 Pavlotsky, F., 1571
 Pecherstorfer, M., 2319
 Pecorelli, S., 2075
 Pellae-Cosset, B., 2260
 Pendergrass, K. B., 1709
 Perez, R. P., 1377
 Perez-Atayde, A., 1833
 Perrone, F., 1772
 Persky, V., 875

Peters, L. J., 319
 Peters, W. P., 2330
 Peterson, D. E., 2550
 Petit, J.-Y., 2260
 Petrella, G., 1772
 Petrovich, Z., 1621
 Petteway, J. C., 2304
 Pettinato, G., 1772
 Pfeleiderer, A., 57
 Phuphanich, S., 1634
 Piazza, E., 1694
 Picco, P., 1662
 Pidlich, J., 1356
 Pierce, S. T., 1564
 Pieretti, M., 650, 1992
 Pierz, D. M., 840
 Pirhonen, J. P., 67, 1214
 Pisters, K. M. W., 774
 Pittelkow, M. R., 1765
 Piver, M. S., 1416
 Pizzo, P. A., 2357
 Pizzolanti, G., 1757
 Plager, C., 1665
 Platt, L. D., 2011
 Plebani, M., 367
 Polansky, M., 1747
 Poon, Y.-F., 413
 Poot, M., 296
 Popp, B., 1283
 Porschen, R., 922
 Portenoy, R. K., 1283
 Post, K. D., 490
 Potter, J. D., 275
 Powell, D. E., 650
 Pradeep, R., 1145
 Preatoni, A., 593
 Preketes, A., 572
 Preti, H. A., 1564
 Priluck, I., 2427
 Pritchard, D. J., 2253
 Province, M. A., 1009
 Pugh, R. P., 1709
 Pukkala, E., 442
 Pylkkänen, L., 1201

Q

Querzoli, P., 2510
 Quint, L. E., 1120

R

Raderer, M., 1356
 Raffeld, M., 1245
 Rahaman, J., 2044
 Rampal, M., 2543
 Ransohoff, J., 840
 Rasmuson, T., 1435
 Rath, F.-W., 1187

Rath, P., 215
 Ravankar, S., 2357
 Ravaud, P., 1559
 Raviv, G., 1440
 Raymond, E., 1344
 Rechavi, G., 2372
 Recht, A., 1491
 Recine, D. C., 2497
 Redmond, H. P., 2418
 Reed, W. P., 967
 Reeves, W. C., 2518
 Regelson, W., 1299
 Reiman, H. M., 1073
 Reinthaller, A., 1786
 Ren, L., 1860
 Resnick, M. B., 187
 Restivo, S., 1757
 Reynès, M., 1344
 Rhys-Evans, P. H., 1051
 Ribbert, H., 550
 Rice, L. W., 1209
 Richards, C. S., 1481
 Richards-Kortum, R., 1956
 Richardson, R. L., 96, 406
 Richart, R. M., 1919
 Richaud, P. M., 1126
 Ridell, B. S., 1261
 Ries, L. A., 237, 1687
 Riley, S., 1150
 Rios, M. B., 992
 Rios-Dalenz, J. L., 1747
 Robinson, E., 589
 Rodenhuis, S., 2338
 Rodriguez, G. I., 1233
 Rodriguez-Martinez, H. A., 1747
 Rogers, L. W., 1197
 Rose, M. A., 880
 Rose, N. R., 2312
 Rosen, G., 1388, 1398
 Rosenberg, S. A., 687
 Rosenthal, A. K., 910
 Rosenthal, S. N., 343
 Rosner, B., 284
 Rosner, G., 2330
 Ross, S. W., 1238
 Roth, J., 479
 Rothman, V. L., 998
 Rouhier, M.-L. P., 1126
 Roux, C., 1559
 Roux, F. J., 1540
 Roveroni, G., 367
 Rozental, J. M., 709
 Rubin, L. A., 1615
 Rudnick, M. R., 497
 Rugge, M., 367, 376
 Runowicz, C. D., 2028
 Russell, A., 1934

Russell, A. H., 1948
 Russo, A., 1757
 Rustgi, A. K., 541
 Rybak, M. E., 1629

S

Sabiston, D. C., Jr., 787
 Sabo, E., 1440
 Sachs, N. E., 1073
 Saegusa, M., 2297
 Saito, K., 1550
 Saito, S., 1043
 Saito, T., 1513
 Saitoh, H., 895
 Saitoh, S., 1139
 Saitoh, Y., 2464
 Sakamaki, H., 602
 Salmi, T. A., 67, 1214
 Samonigg, H., 2319
 Samuel, D., 1344
 Sano, T., 618
 Sarbia, M., 922
 Sarrazin, D., 2260
 Sartor, O., 453
 Sasajima, H., 1224
 Sasajima, T., 1224
 Sasaki, K., 1132
 Sasaki, M., 91, 1790
 Sasaki, T., 941
 Sato, C., 2211
 Sato, K., 86
 Sato, T., 1132
 Satoh, M., 1043
 Sault, M.-C., 2543
 Sausville, E. A., 453
 Sawada, T., 1086
 Sawada, Y., 1513
 Sawyer, J. R., 1238, 1853
 Scapoli, D., 2510
 Scarabelli, C., 1019
 Scaradavou, A., 1860
 Scardis, P. T., 2530
 Schapira, D. V., 243
 Scheithauer, B. W., 4
 Scheithauer, W., 1356
 Schenk, T., 1356
 Schettino, F., 1601
 Schiffman, M. H., 1888
 Schlag, P. M., 1700
 Schmidt, D., 1073
 Schmidt, H., 1187
 Schmidt, R., 497
 Schmitt, B., 57
 Schneider, P. M., 178
 Schneiders, A., 720
 Schnitt, S. J., 1
 Schriber, J. R., 860
 Schröder, F. H., 129
 Schroeder, G., 1059
 Schroy, P. C., III, 201
 Schubert, M. M., 2550
 Schuller, D., 1233
 Schultz, D., 2242
 Schulz, F., 1356
 Schulz, G., 510
 Schumacher, L. Y., 1398
 Schutt, A. J., 961
 Schuyler, P. A., 1197
 Schwartz, P. E., 1987, 1998, 2133
 Schwartzentruber, D. J., 687
 Schweitzer, V. G., 1069
 Schwonzen, M., 954
 Scott, C. B., 307
 Seidman, A. D., 232
 Seipp, C. A., 687
 Seki, K., 618
 Sell, K. W., 824
 Sellers, T. A., 275
 Sengeløv, L., 1797
 Serraino, D., 333
 Sevin, B.-U., 1978
 Shafir, R., 1571
 Shannon, K., 674
 Shannon, V. R., 437
 Sharon, N., 2372
 Sharp, G. B., 1116
 Shatskaya, V. A., 2524
 Shaw, E. G., 406
 Shenson, D. L., 650
 Shi, Y., 314
 Shibasaki, M., 895
 Shibuya, H., 101
 Shih, A., 291
 Shih, R. T.-P., 291
 Shimada, H., 1073, 2363
 Shin, D. M., 2230
 Shindoh, M., 1513
 Shingleton, H. M., 1411, 1934, 1948
 Shino, Y., 1529, 2193
 Shinohara, N., 972
 Shirakawa, S., 2351
 Shirouzu, K., 388, 393
 Shives, T. C., 2471
 Shoji, Y., 2297
 Shu, C. H., 2186
 Sideri, M., 1601
 Siegal, J. A., 2304
 Siewert, J. R., 178
 Signaroldi, A., 1694
 Sikora, S. S., 1145
 Simms, W. W., 223
 Simoneau, A. R., 833
 Sioutos, P. J., 1453
 Sjövall, K., 2004
 Skates, S. J., 2004
 Skinner, D. G., 833, 1621
 Skinner, E. C., 833
 Sklar, C. A., 1860
 Sliutz, G., 1786
 Slominski-Castor, S., 2427
 Small, E. J., 1428
 Smirniotopoulos, J. G., 1155
 Smith, P. M., 2133
 Smith, R., 2518
 Smith, R. E., 1233
 Smitt, M. C., 259
 Smyrk, T., 2427
 Snyder, C. S., 1545
 So, M. K. P., 2443
 Solomon, M. P., 998
 Soloway, R. D., 1747
 Sommer, H. M., 1809
 Sonego, F., 376
 Sørensen, F. B., 797
 Sorio, R., 333
 Spann, C. O., 2518
 Sparen, P., 442
 Speizer, F. E., 284
 Spielmann, M., 2286
 Spinaci, L., 1601
 Spolti, N., 1601
 Springer, G. F., 1700
 Srinivas, S., 1428
 Srivastava, G., 658
 Stäbler, A., 1460
 Staddon, A., 497
 Stadler, W. M., 1629
 Stampfer, M. J., 284
 Standaert, B., 129
 Stark, A. J., 967
 Stass, S. A., 985, 992
 Stathopoulos, G. P., 1253
 Stein, J. P., 833
 Steinbach, G., 919
 Steinberg, S. M., 453
 Stengel, A., 1460
 Stenson, M. J., 1059
 Stettner, H. M., 1302
 Stewart, G. J., 572
 Stockdale, F. E., 259
 Storlie, J. A., 96
 Storm, H. H., 442
 Street, R. L., Jr., 2275
 Strom, B. L., 1747
 Suehiro, T., 399
 Suganuma, N., 2565
 Sugimachi, K., 399
 Sugimoto, T., 1086
 Sugioaka, Y., 972
 Suh, Y. K., 1545
 Sullivan, J. W., 328

Sumazaki, R., 895
 Sundal, E., 2319
 Surwit, E. A., 2113
 Suyama, K., 463
 Suzuki, Y., 1139
 Swain, S. M., 2485
 Swanson, C. M., 1238
 Swanson, G. P., 2275
 Swenson, K. K., 880
 Swern, A. S., 2266
 Synnestvedt, M., 2242

T

Tafi, A., 1737
 Takada, N., 358
 Takagi, K., 1275
 Takahashi, H., 928
 Takano, Y., 2297
 Takenaka, A., 750
 Takenaka, T., 602
 Takeshita, A., 602
 Takeuchi, L. A., 2363
 Takita, H., 895
 Talpaz, M., 609, 992
 Tamakoshi, A., 2565
 Tamakoshi, K., 2565
 Tamakuma, S., 935
 Tanabe, M., 1086
 Tanaka, K., 1445
 Tanaka, T., 1086, 2449
 Tanaka, W., 2449
 Tanaka, Y., 2211, 2312
 Tanase, M., 1529, 2193
 Tang, L., 2211
 Tang, R., 1724
 Tangen, C., 715
 Tango, T., 743
 Tanzer, J. M., 2550
 Tarraza, H. M., 1209
 Tartter, P. I., 268
 Tatangelo, F., 1585
 Tateishi, R., 1368
 Tatsumi, M., 2193
 Tatsuta, M., 750
 Taubert, H., 1187
 Taubert, J. K., 1268
 Teixeira, M. R., 250
 Testa, A., 1821
 Tetzner, C., 1356
 Thamm, B., 1187
 Thibault, A., 453
 Thibodeau, S. N., 1765
 Thomas, B. L. M., 2338
 Thomas, F., 2286
 Thoms, W. W., 2518
 Tickle, S. P., 700
 Tilchen, E. J., 1655
 Timmerman, T. G., 669

Timmons, C. F., 1481
 Tirrito, M. L., 1821
 Tiseo, P. J., 1283
 Togawa, K., 541
 Tomás, E. I., 1406
 Tomasino, R. M., 1757
 Tomaszewski, J. E., 497
 Tomimatsu, S., 935
 Tomita, S. S., 121
 Tomoda, Y., 2565
 Tomura, N., 1224
 Tong, J. Y., 1467
 Toogood, P. B., 644
 Toomey, D., 2418
 Topalian, S. L., 687
 Toren, A., 2372
 Torgerson, J. S., 1261
 Tortolero-Luna, G., 1956
 Trau, H., 1571
 Triche, T. J., 1073, 2363
 Tricottet, V., 1344
 Trimbo, J. B., 807
 Tripathi, S. P., 1006
 Trock, B., 2485
 Trock, B. J., 163
 Tryka, A. F., 1853
 Tsang, W. Y. W., 413
 Tsatalpas, P., 296
 Tsachachler, E., 1786
 Tsokos, M. G., 1073
 Tsubota, A., 1139
 Tsuchiya, A., 32
 Tsuneyoshi, M., 972, 1313
 Tuchman, M., 2363
 Tumminello, F. M., 1757
 Tursz, T., 2286
 Tuszyński, G. P., 998
 Tutschka, P., 2550
 Tyson, L. B., 774

U

Uchida, T., 463
 Ueda, M., 2504
 Uefuji, K., 935
 Uehara, H., 750
 Uemura, K., 1224
 Uesaka, Y., 1224
 Uesugi, N., 1132
 Ukita, M., 72
 Umsawasdi, T., 2230
 Unger, E. R., 2518
 Unni, K. K., 1550, 2471

V

Vaickus, L., 1377
 Val-Bernal, J. F., 1181
 Valenza, R., 1821
 VandenBerg, S. R., 4

van der Lelie, H., 2338
 van Dijk, M. A., 2338
 van Dijken, P. J., 517
 van Doornewaard, G., 638
 Van Laethem, J.-L., 1166
 van Leeuwen, E. F., 339
 van Nagell, J. R., Jr., 1992, 2086
 van Oers, R. H. J., 2338
 van Tinteren, H., 638
 van Unnik, A. J. M., 1073
 Varhaug, J. E., 1643
 Varriale, E., 1772
 Vázquez-Barquero, A., 1181
 Veeder, M. H., 961
 Vernava, A. M., 1325
 Vernon, S. D., 2518
 Vernon, S. W., 46
 Verschraegen, C. F., 992
 Verwijs, W., 517
 Vierbuchen, M., 954
 Vierbuchen, M. J., 727
 Vinh, T. N., 1155
 Virgo, K. S., 1325
 Visentin, M. C., 1019
 Vitols, S., 423
 Vlamis, V., 824
 Vogel, C. L., 2485
 Vogel, V. G., 46
 Vogelzang, N. J., 824, 1629
 Volgt, B., 2275
 Vollmers, H. P., 550
 von dem Borne, A. E. G. Kr., 2338
 von der Maase, H., 1797
 Voutilainen, R. J., 1406
 Vuento, M. H., 1214

W

Wada, A., 750
 Wade, J. L., III, 1709
 Wade, T. P., 1325
 Wakasa, H., 32
 Wakeley, C. J., 1846
 Wakita, T., 101
 Walsh, G., 2230
 Walsh, T. J., 2357
 Walther, P. J., 824
 Wan, S.-K., 1689
 Wang, H., 1606
 Wang, H. H., 187
 Wang, H.-J., 2491
 Wang, J. Y., 1724
 Wanibuchi, H., 358
 Warner, D., 116
 Wasdhal, D. A., 2253
 Watanabe, A., 1529, 2193
 Watanabe, T., 358
 Weaver, M. L., 210

Weaver-McClure, L., 2557
 Webber, B. L., 1073
 Weber, D. M., 46
 Weber, J. S., 687
 Weinberger, D., 2266
 Weiss, G. R., 2248
 Weiss, S. E., 268
 Weitzner, M. A., 1804
 Wenger, D. E., 2471
 Wenig, B. M., 1155, 2217
 Wennerberg, J. P., 853
 Werner, M. H., 1634
 West, S. L., 1747
 Westergaard, T., 106
 Wetzler, M., 609
 Wexler, L. H., 2557
 Wharton, J. T., 1956
 Wheeler, T. M., 2530
 Whitcomb, P. O., 2357
 White, D. E., 687
 Whitney, J. F., 20
 Whittemore, A. S., 1416
 Whyte, R. I., 1120
 Widemann, B. C., 521
 Wieand, H. S., 961
 Wiener, E. S., 121
 Wiernik, P. H., 2237
 Wile, A. G., 2075
 Wilkes, J. D., 1377
 Willén, R., 853
 Willers, R., 922
 Willett, W. C., 284
 Winchester, D. J., 1476
 Winchester, D. P., 1934, 1948
 Winn, R. J., 1709
 Wiseman, G. A., 96
 Witzig, T. E., 1059
 Wolfe, W. G., 787
 Wollan, P. C., 1550, 2471
 Woloschak, M., 490

Woods, W. G., 2363
 Woolas, R. P., 1615
 Wozniak, E., 550
 Wright, T. C., 1902
 Wright, T. C., Jr., 1591
 Wroński, M., 765
 Würfl, P., 1187

X

Xu, F.-J., 2004

Y

Yahara, T., 935
 Yamabe, H., 429, 1790
 Yamada, O., 602
 Yamada, T., 1529, 2193
 Yamada, Y., 1529, 2193
 Yamagata, S., 2565
 Yamaguchi, M., 2351
 Yamaguchi, Y., 2464
 Yamamoto, K., 399
 Yamamoto, S., 743
 Yamanaka, N., 2449
 Yamasaki, K., 1275
 Yamashita, J., 1529, 2193
 Yang, C.-H., 291
 Yang, J. C., 687
 Yang, P., 618
 Yang, R.-S., 1388, 1398
 Yang, S., 201
 Yano, N., 72
 Yao, T., 1313
 Yasuda, K., 1352
 Yasuda, M., 1513
 Yasumoto, M., 101
 Yen, S. H., 2186
 Yeomans-Kinney, A., 46
 Yernault, J.-C., 1166
 Yi, E. S., 1545
 Ying, W., 79
 Yip, T. T. C., 413, 1689

Yokouchi, H., 1368, 1779
 Yokoyama, A., 928
 Yokoyama, E., 463
 Yokoyama, T., 928
 Yonemura, Y., 941
 Yoshida, O., 1790
 Yoshida, S., 1275
 Yoshino, K., 928
 Yotsuyanagi, H., 1352
 You, Y. T., 1724
 Younes, M., 1150
 Young, W. G., Jr., 787
 Youssef, E. M., 358
 Yu, A., 490
 Yu, E., 2304
 Yu, Y.-H., 2004

Z

Zafar, N., 1065
 Zalcberg, J., 228
 Zaniboni, A., 1694
 Zarrabi, H., 1330
 Zarrabi, H. M., 700
 Zarrelli, A., 1019
 Zätterström, U. K., 853
 Zdeblick, M. J., 259
 Zemel, R., 210
 Zenahlik, P., 26
 Zhang, S., 275
 Zhou, J., 429
 Zienkiewicz, T. J., 727
 Zimmerman, G. C., 110
 Zimmerman, K., 2557
 Zippin, C., 2343
 Zou, M., 314
 Zuber-Ocwieja, K. E., 1934
 Zucker, S., 700
 Zukerberg, L., 541
 Zwas, S. T., 215

